


What is claimed is:

1. A compound of the formula:



wherein

Z is  $-C(R_{18})(R_{19})-$  or  $-C(O)-$  wherein  $R_{18}$  and  $R_{19}$  are independently selected from hydrogen and loweralkyl;

n is 0 or 1;

R is  $-(CH_2)_m-W$  wherein m is an integer from 0 to 6 and W is

(a)  $-C(O)_2-G$  wherein G is hydrogen or a carboxy protecting group,

(b)  $-PO_3H_2$ ,

(c)  $-P(O)(OH)E$  wherein E is hydrogen, loweralkyl or arylalkyl,

(d)  $-CN$ ,

(e)  $-C(O)NHR_{17}$  wherein  $R_{17}$  is loweralkyl,

(f) alkylaminocarbonyl,

(g) dialkylaminocarbonyl,

(h) tetrazolyl,


(i) hydroxy,

(j) alkoxy,


(k) sulfonamido,

(l)  $-C(O)NHS(O)_2R_{16}$  wherein  $R_{16}$  is loweralkyl, haloalkyl, aryl or dialkylamino,

(m)  $-S(O)_2NHC(O)R_{16}$  wherein  $R_{16}$  is defined as above,



(n)



$R_1$  and  $R_2$  are independently selected from hydrogen, loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl and  $(R_{aa})(R_{bb})N-R_{cc}$  wherein  $R_{aa}$  is aryl or arylalkyl,  $R_{bb}$  is hydrogen or alkanoyl and  $R_{cc}$  is alkylene, with the proviso that one or both of  $R_1$  and  $R_2$  is other than hydrogen;

$R_3$  is (a)  $R_4-C(O)-R_5$ ,  $R_4-R_{5a}$ ,  $R_4-C(O)-R_5-N(R_6)-$ ,  $R_6-S(O)_2-R_7$  or  $R_{26}-S(O)-R_{27}$ -

wherein R<sub>5</sub> is (i) a covalent bond, (ii) alkylene, (iii) alkenylene, (iv) -N(R<sub>20</sub>)-R<sub>8</sub>- or -R<sub>8a</sub>-N(R<sub>20</sub>)-R<sub>8</sub>-

wherein R<sub>8</sub> and R<sub>8a</sub> are independently selected from the group consisting of alkylene and alkenylene and R<sub>20</sub> is hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, cycloalkyl or cycloalkylalkyl or (v) -O-R<sub>9</sub>- or -R<sub>9a</sub>-O-R<sub>9</sub>- wherein R<sub>9</sub> and R<sub>9a</sub> are independently selected from alkylene;

R<sub>5a</sub> is (i) alkylene or (ii) alkenylene;

R<sub>7</sub> is (i) a covalent bond, (ii) alkylene, (iii) alkenylene or (iv) -N(R<sub>21</sub>)-R<sub>10</sub>- or -R<sub>10a</sub>-N(R<sub>21</sub>)-R<sub>10</sub>- wherein R<sub>10</sub> and R<sub>10a</sub> are independently selected from the group consisting of alkylene and alkenylene and R<sub>21</sub> is hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl;

R<sub>4</sub> and R<sub>6</sub> are independently selected from the group consisting of

(i) (R<sub>11</sub>)(R<sub>12</sub>)N- wherein R<sub>11</sub> and R<sub>12</sub> are independently selected from

- (1) hydrogen,
- (2) loweralkyl,
- (3) haloalkyl,
- (4) alkoxyalkyl,
- (5) haloalkoxyalkyl,
- (6) alkenyl,
- (7) alkynyl,
- (8) cycloalkyl,
- (9) cycloalkylalkyl,
- (10) aryl,
- (11) heterocyclic,
- (12) arylalkyl,
- (13) (heterocyclic)alkyl,
- (14) hydroxyalkyl,
- (15) alkoxy,
- (16) aminoalkyl,
- (17) trialkylaminoalkyl,
- (18) alkylaminoalkyl,
- (19) dialkylaminoalkyl, and
- (20) carboxyalkyl


(ii) loweralkyl,

(iii) alkenyl,

(iv) alkynyl,

(v) cycloalkyl,

- (vi) cycloalkylalkyl,
- (vii) aryl,
- (viii) arylalkyl,
- (ix) heterocyclic,
- (x) (heterocyclic)alkyl,
- (xi) alkoxyalkyl,
- (xii) hydroxyalkyl,
- (xiii) haloalkyl,
- (xiv) haloalkenyl,
- (xv) haloalkoxyalkyl,
- (xvi) haloalkoxy,
- (xvii) alkoxyhaloalkyl,
- (xviii) alkylaminoalkyl,
- (xix) dialkylaminoalkyl,
- (xx) alkoxy, and



wherein z is 0-5 and  $R_{7a}$  is alkylene;

$R_{26}$  is (i) loweralkyl, (ii) haloalkyl, (iii) alkenyl, (iv) alkynyl, (v) cycloalkyl, (vi) cycloalkylalkyl, (vii) aryl, (viii) arylalkyl, (ix) heterocyclic, (x) (heterocyclic)alkyl, (xi) alkoxyalkyl or (xii) alkoxy-substituted haloalkyl; and  $R_{27}$  is alkylene or alkenylene;

(b)  $R_{22}-O-C(O)-R_{23}$ - wherein  $R_{22}$  is a carboxy protecting group or heterocyclic and  $R_{23}$  is (i) a covalent bond, (ii) alkylene, (iii) alkenylene or (iv)  $-N(R_{24})-R_{25}$ - wherein  $R_{25}$  is alkylene and  $R_{24}$  is hydrogen or loweralkyl,

- (c) loweralkyl,
- (d) alkenyl,
- (e) alkynyl,
- (f) cycloalkyl,
- (g) cycloalkylalkyl,
- (h) aryl,
- (i) arylalkyl,
- (j) aryloxyalkyl,

- (k) heterocyclic,
- (l) (heterocyclic)alkyl,
- (m) alkoxyalkyl,
- (n) alkoxyalkoxyalkyl, or
- (o)  $R_{13}-C(O)-CH(R_{14})-$

wherein  $R_{13}$  is amino, alkylamino or dialkylamino and  $R_{14}$  is aryl or  $R_{15}-C(O)-$  wherein  $R_{15}$  is amino, alkylamino or dialkylamino; or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1 wherein n is 0 and Z is  $-CH_2-$ .

3. The compound according to Claim 1 wherein n is 1 and Z is  $-CH_2-$ .

4. The compound according to Claim 1 wherein n is 0, Z is  $-CH_2-$ , and  $R_3$  is  $R_4-C(O)-R_5-$ ,  $R_6-SO_2-R_7-$  or  $R_{26}-S(O)-R_{27}-$  wherein  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_{26}$  and  $R_{27}$  are as defined therein.

5. The compound according to Claim 1 wherein n is 0, Z is  $-CH_2-$ , and  $R_3$  is alkoxyalkyl or alkoxyalkoxyalkyl.

6. The compound according to Claim 1 wherein n is 0, Z is  $-CH_2-$ , and  $R_3$  is  $R_4-C(O)-R_5-$  wherein  $R_4$  is  $(R_{11})(R_{12})N-$  as defined therein and  $R_5$  is alkylene or  $R_3$  is  $R_6-S(O)_2-R_7-$  or  $R_{26}-S(O)-R_{27}-$  wherein  $R_7$  is alkylene,  $R_{27}$  is alkylene and  $R_6$  and  $R_{26}$  are as defined therein.

7. The compound according to Claim 1 wherein n is 0, Z is  $-CH_2-$  and  $R_3$  is  $R_4-C(O)-N(R_{20})-R_8-$  or  $R_6-S(O)_2-N(R_{21})-R_{10}-$  wherein  $R_8$  and  $R_{10}$  are alkylene and  $R_4$ ,  $R_6$ ,  $R_{20}$  and  $R_{21}$  are as defined therein.

8. The compound according to Claim 1 wherein n is 0, R is tetrazolyl or  $-C(O)_2-G$  wherein G is hydrogen or a carboxy protecting group or R is tetrazolyl or R is  $-C(O)-NHS(O)_2R_{16}$  wherein  $R_{16}$  is loweralkyl, haloalkyl or aryl, Z is  $-CH_2-$ ,  $R_1$  and  $R_2$  are independently selected from (i) loweralkyl, (ii) cycloalkyl, (iii) substituted and unsubstituted aryl wherein aryl is phenyl substituted with one, two or three substituents independently selected from

loweralkyl, alkoxy, halo, alkoxyalkoxy and carboxyalkoxy, (iv) substituted or unsubstituted heterocyclic, (v) alkenyl, (vi) heterocyclic (alkyl), (vii) aryloxyalkyl, (viii) arylalkyl, (ix) (N-alkanoyl-N-alkyl)aminoalkyl, and (x) alkylsulfonylamidoalkyl, and  $R_3$  is  $R_4-C(O)-R_5-$  wherein  $R_4$  is  $(R_{11})(R_{12})N-$  wherein  $R_{11}$  and  $R_{12}$  are independently selected from loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, heterocyclic, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, aryl and arylalkyl and  $R_5$  is alkylene; or  $R_3$  is  $R_4-C(O)-N(R_{20})-R_8-$  or  $R_6-S(O)_2-N(R_{21})-R_{10}-$  wherein  $R_4$  is loweralkyl, aryl, alkoxy, alkylamino, aryloxy or arylalkoxy and  $R_6$  is loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl,  $R_8$  and  $R_{10}$  are alkylene and  $R_{20}$  and  $R_{21}$  are loweralkyl; or  $R_3$  is  $R_6-S(O)_2-R_7-$  or  $R_{26}-S(O)-R_{27}-$  wherein  $R_6$  is loweralkyl or haloalkyl,  $R_7$  is alkylene,  $R_{26}$  is loweralkyl and  $R_{27}$  is alkylene.

9. The compound according to Claim 1 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group, tetrazolyl or  $-C(O)-NHS(O)_2R_{16}$  wherein  $R_{16}$  is loweralkyl, haloalkyl or aryl,  $Z$  is  $-CH_2-$ ,  $R_1$  is (i) loweralkyl, (ii) alkenyl, (iii) alkoxyalkyl, (iv) cycloalkyl, (v) phenyl, (vi) pyridyl, (vii) furanyl or (viii) substituted or unsubstituted 4-methoxyphenyl, 4-fluorophenyl, 3-fluorophenyl, 4-ethoxyphenyl, 4-ethylphenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 3-fluoro-4-methoxyphenyl, 3-fluoro-4-ethoxyphenyl, 2-fluorophenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-*t*-butylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from alkoxy, alkoxyalkoxy and carboxyalkoxy, (ix) arylalkyl, (x) aryloxyalkyl, (xi) heterocyclic (alkyl), (xii) (N-alkanoyl-N-alkyl)aminoalkyl, or (xiii) alkylsulfonylamidoalkyl,  $R_2$  is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl, or difluorophenyl, and  $R_3$  is  $R_4-C(O)-N(R_{20})-R_8-$  or  $R_6-S(O)_2-N(R_{21})-R_{10}-$  wherein  $R_8$  and  $R_{10}$  are alkylene,  $R_{20}$  and  $R_{21}$  are loweralkyl,  $R_4$  is loweralkyl, aryl, alkoxy, alkylamino, aryloxy or arylalkoxy and  $R_6$  is loweralkyl, haloalkyl, alkoxyalkyl, aryl or arylalkyl.

10. The compound according to Claim 1 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group, tetrazolyl or  $-C(O)-NHS(O)_2R_{16}$  wherein  $R_{16}$  is loweralkyl, haloalkyl or aryl,  $Z$  is  $-CH_2-$ ,  $R_1$  is (i) loweralkyl, (ii) alkenyl, (iii) alkoxyalkyl, (iv) cycloalkyl, (v) phenyl, (vi) pyridyl,

(vii) furanyl or (viii) substituted or unsubstituted 4-methoxyphenyl, 4-fluorophenyl, 3-fluorophenyl, 4-ethoxyphenyl, 4-ethylphenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 3-fluoro-4-methoxyphenyl, 3-fluoro-4-ethoxyphenyl, 2-fluorophenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-*t*-butylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from alkoxy, alkoxyalkoxy and carboxyalkoxy, (ix) arylalkyl, (x) aryloxyalkyl, (xi) heterocyclic (alkyl), (xii) (N-alkanoyl-N-alkyl)aminoalkyl or (xiii) alkylsulfonylamidoalkyl,  $R_2$  is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl, or difluorophenyl, and  $R_3$  is  $R_4-C(O)-R_5$ - wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N$ - wherein  $R_{11}$  and  $R_{12}$  are independently selected from loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl, arylalkyl, heterocyclic, hydroxyalkyl, alkoxy, aminoalkyl, and trialkylaminoalkyl.

11. The compound according to Claim 1 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group, tetrazolyl or  $-C(O)-NHS(O)_2R_{16}$  wherein  $R_{16}$  is loweralkyl, haloalkyl or aryl,  $Z$  is  $-CH_2-$ ,  $R_1$  is (i) loweralkyl (ii) alkenyl, (iii) arylalkyl, (iv) aryloxyalkyl, (v) heterocyclic, (vi) heterocyclic (alkyl), (vii) aryl, (viii) (N-alkanoyl-N-alkyl)aminoalkyl, or (ix) alkylsulfonylamidoalkyl,  $R_2$  is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the substituent is selected from loweralkyl, alkoxy and halogen and  $R_3$  is  $R_4-C(O)-R_5$ - wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N$ - wherein  $R_{11}$  is loweralkyl, and  $R_{12}$  is aryl or arylalkyl.

12. The compound according to Claim 1 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group, tetrazolyl or  $-C(O)-NHS(O)_2R_{16}$  wherein  $R_{16}$  is loweralkyl, haloalkyl or aryl,  $Z$  is  $-CH_2-$ ,  $R_1$  is (i) phenyl or (ii) substituted or unsubstituted 4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 3-fluorophenyl, 3-fluoro-4-ethoxyphenyl, 2-fluorophenyl, 4-methoxymethoxyphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from loweralkyl, haloalkyl, alkoxy, alkoxyalkoxy, and carboxyalkoxy,  $R_2$  is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-

benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the substituent is selected from loweralkyl, alkoxy and halogen and  $R_3$  is  $R_6-S(O)_2-N(R_{21})-R_{10}$ - wherein  $R_{10}$  is alkylene,  $R_6$  is loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl and  $R_{21}$  is loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl.

13. The compound according to Claim 1 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group, tetrazolyl or  $-C(O)-NHS(O)_2R_{16}$  wherein  $R_{16}$  is loweralkyl, haloalkyl or aryl,  $Z$  is  $-CH_2-$ ,  $R_1$  is substituted or unsubstituted 4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 3-fluorophenyl, 3-fluoro-4-ethoxyphenyl, 4-methoxymethoxyphenyl, 1,3-benzodioxolyl or 1,4-benzodioxanyl wherein the substituent is selected from loweralkyl, haloalkyl, alkoxy and alkoxyalkoxy,  $R_2$  is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the substituent is selected from loweralkyl, alkoxy and halogen and  $R_3$  is alkoxycarbonyl or  $R_6-S(O)_2-N(R_{21})-R_{10}$ - wherein  $R_{10}$  is alkylene,  $R_6$  is loweralkyl, haloalkyl, alkoxyalkyl or haloalkoxyalkyl and  $R_{21}$  is loweralkyl, haloalkyl, alkoxyalkyl or haloalkoxyalkyl.

14. The compound according to Claim 1 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group, tetrazolyl or  $-C(O)-NHS(O)_2R_{16}$  wherein  $R_{16}$  is loweralkyl or haloalkyl,  $Z$  is  $-CH_2-$ ,  $R_1$  is substituted or unsubstituted 4-methoxyphenyl, 4-fluorophenyl, 2-fluorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-ethylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from alkoxy, alkoxyalkoxy and carboxyalkoxy,  $R_2$  is 1,3-benzodioxolyl, 1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl and  $R_3$  is  $R_4-C(O)-R_5$ - wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N$ - wherein  $R_{11}$  and  $R_{12}$  are independently selected from loweralkyl, aryl, arylalkyl, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, and heterocyclic.



15. The compound according to Claim 1 wherein n is 0, R is  $-C(O)_2-G$  wherein G is hydrogen or a carboxy protecting group, tetrazolyl or  $-C(O)-NHS(O)_2R_{16}$

wherein  $R_{16}$  is loweralkyl or haloalkyl, Z is  $-CH_2-$ ,  $R_1$  is loweralkyl, alkoxyalkyl, or alkenyl,  $R_2$  is 1,3-benzodioxolyl, 1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl and  $R_3$  is  $R_4-C(O)-R_5$

wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N-$

wherein  $R_{11}$  and  $R_{12}$  are independently selected from loweralkyl, aryl hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, heterocyclic, and arylalkyl.

16. The compound according to Claim 1 wherein n is 0, R is  $-C(O)_2-G$  wherein G is hydrogen or a carboxy protecting group, Z is  $-CH_2-$ ,  $R_1$  is

substituted or unsubstituted 4-methoxyphenyl, 4-fluorophenyl, 2-fluorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-ethylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from alkoxy, alkoxyalkoxy and carboxyalkoxy,  $R_2$  is 1,3-benzodioxolyl, 1,4-

benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl and  $R_3$  is  $R_4-C(O)-R_5$  wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N-$  wherein  $R_{11}$  and  $R_{12}$  are independently selected from loweralkyl, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, aryl, and heterocyclic.

17. The compound according to Claim 1 wherein n is 0, R is  $-C(O)_2-G$  wherein G is hydrogen or a carboxy protecting group, Z is  $-CH_2-$ ,  $R_1$  is

substituted or unsubstituted 4-methoxyphenyl, 4-fluorophenyl, 2-fluorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-ethylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from alkoxy, alkoxyalkoxy and carboxyalkoxy,  $R_2$  is 1,3-benzodioxolyl, 1,4-

benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl and  $R_3$  is  $R_4-C(O)-R_5$


wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N-$  wherein  $R_{11}$  is loweralkyl and  $R_{12}$  is aryl.

18. The compound according to Claim 1 wherein n is 0, R is -C(O)<sub>2</sub>-G wherein G is hydrogen or a carboxy protecting group, Z is -CH<sub>2</sub>-, R<sub>1</sub> is substituted or unsubstituted 4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 3-fluorophenyl, 2-fluorophenyl, 3-fluoro-4-ethoxyphenyl, 4-methoxymethoxyphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from loweralkyl, haloalkyl, alkoxy, alkoxyalkoxy and carboxyalkoxy, R<sub>2</sub> is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the substituent is selected from loweralkyl, alkoxy and halogen and R<sub>3</sub> is R<sub>4</sub>-C(O)-R<sub>5</sub>- wherein R<sub>5</sub> is alkylene and R<sub>4</sub> is (R<sub>11</sub>)(R<sub>12</sub>)N- wherein R<sub>11</sub> is alkyl and R<sub>12</sub> is selected from aryl, aminoalkyl, trialkylaminoalkyl, and heterocyclic.

19. A compound according to Claim 1 wherein n is 0, R is -C(O)<sub>2</sub>-G wherein G is hydrogen or a carboxy protecting group, Z is -CH<sub>2</sub>-, R<sub>1</sub> is loweralkyl, alkenyl, heterocyclic (alkyl), aryloxyalkyl, aryalkyl, aryl, (N-alkanoyl-N-alkyl)aminoalkyl, or alkylsulfonylamidoalkyl, and R<sub>3</sub> is R<sub>4</sub>-C(O)-R<sub>5</sub>- wherein R<sub>5</sub> is alkylene and R<sub>4</sub> is (R<sub>11</sub>)(R<sub>12</sub>)N- wherein R<sub>11</sub> and R<sub>12</sub> are independently selected from alkyl, aryl, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, and heterocyclic.

20. A compound according to Claim 1 wherein n is 0, R is -C(O)<sub>2</sub>-G wherein G is hydrogen or a carboxy protecting group, Z is -CH<sub>2</sub>-, R<sub>1</sub> is loweralkyl, alkenyl, heterocyclic (alkyl), aryloxyalkyl, aryalkyl, aryl, (N-alkanoyl-N-alkyl)aminoalkyl, or alkylsulfonylamidoalkyl, and R<sub>3</sub> is R<sub>4</sub>-C(O)-R<sub>5</sub>- wherein R<sub>5</sub> is alkylene and R<sub>4</sub> is (R<sub>11</sub>)(R<sub>12</sub>)N- wherein R<sub>11</sub> and R<sub>12</sub> are independently selected from alkyl, aryl, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, and heterocyclic, with the proviso that one or R<sub>11</sub> and R<sub>12</sub> is alkyl.

21. The compound according to Claim 1 of the formula:



wherein

Z is  $-C(R_{18})(R_{19})-$  or  $-C(O)-$  wherein  $R_{18}$  and  $R_{19}$  are independently selected from hydrogen and loweralkyl;

5 n is 0 or 1;

R is  $-(CH_2)_m-W$  wherein m is an integer from 0 to 6 and W is

(a)  $-C(O)_2-G$  wherein G is hydrogen or a carboxy protecting group,

(b)  $-PO_3H_2$ ,

(c)  $-P(O)(OH)E$  wherein E is hydrogen, loweralkyl or arylalkyl,

10

(d)  $-CN$ ,

(e)  $-C(O)NHR_{17}$  wherein  $R_{17}$  is loweralkyl,

(f) alkylaminocarbonyl,

(g) dialkylaminocarbonyl,

(h) tetrazolyl,

15

(i) hydroxy,


(j) alkoxy,

(k) sulfonamido,


(l)  $-C(O)NHS(O)_2R_{16}$  wherein  $R_{16}$  is loweralkyl, haloalkyl, aryl or dialkylamino,

20


(m)  $-S(O)_2NHC(O)R_{16}$  wherein  $R_{16}$  is defined as above,




(n)




(o)



(p)



(q)



- 5 R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen, loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl,
- 10 alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl and (R<sub>aa</sub>)(R<sub>bb</sub>)N-R<sub>cc</sub>- wherein R<sub>aa</sub> is aryl or arylalkyl, R<sub>bb</sub> is hydrogen or alkanoyl and R<sub>cc</sub> is alkylene, with the proviso that one or both of R<sub>1</sub> and R<sub>2</sub> is other than
- 15 hydrogen;
- R<sub>3</sub> is (a) R<sub>4</sub>-C(O)-R<sub>5</sub>-, R<sub>4</sub>-R<sub>5a</sub>-, R<sub>6</sub>-S(O)<sub>2</sub>-R<sub>7</sub>- or R<sub>26</sub>-S(O)-R<sub>27</sub>- wherein R<sub>5</sub> is (i) a covalent bond, (ii) alkylene, (iii) alkenylene, (iv) -N(R<sub>20</sub>)-R<sub>8</sub>- or -R<sub>8a</sub>-N(R<sub>20</sub>)-R<sub>8</sub>- wherein R<sub>8</sub> and R<sub>8a</sub> are independently selected from the group consisting of
- 20 alkylene and alkenylene and R<sub>20</sub> is hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, cycloalkyl or cycloalkylalkyl or (v) -O-R<sub>9</sub>- or -R<sub>9a</sub>-O-R<sub>9</sub>- wherein R<sub>9</sub> and R<sub>9a</sub> are independently selected from alkylene;
- R<sub>5a</sub> is (i) alkylene or (ii) alkenylene;
- 25 R<sub>7</sub> is (i) a covalent bond, (ii) alkylene, (iii) alkenylene or (iv) -N(R<sub>21</sub>)-R<sub>10</sub>- or -R<sub>10a</sub>-N(R<sub>21</sub>)-R<sub>10</sub>-

wherein  $R_{10}$  and  $R_{10a}$  are independently selected from the group consisting of alkylene and alkenylene and  $R_{21}$  is hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl;

$R_4$  and  $R_6$  are independently selected from the group consisting of

5 (i)  $(R_{11})(R_{12})N-$  wherein  $R_{11}$  and  $R_{12}$  are independently selected from

- (1) hydrogen,
- (2) loweralkyl,
- (3) haloalkyl,
- 10 (4) alkoxyalkyl,
- (5) haloalkoxyalkyl,
- (6) alkenyl,
- (7) alkynyl,
- (8) cycloalkyl,
- 15 (9) cycloalkylalkyl,
- (10) aryl,
- (11) heterocyclic,
- (12) arylalkyl,
- (13) (heterocyclic)alkyl,
- 20 (14) hydroxyalkyl,
- (15) alkoxy,
- (16) aminoalkyl, and
- (17) trialkylaminoalkyl,

(ii) loweralkyl,

25 (iii) alkenyl,

(iv) alkynyl,

(v) cycloalkyl,

(vi) cycloalkylalkyl,

(vii) aryl,

30 (viii) arylalkyl,

(ix) heterocyclic,

(x) (heterocyclic)alkyl,

(xi) alkoxyalkyl,

(xii) hydroxyalkyl,


35 (xiii) haloalkyl,

(xiv) haloalkenyl,

(xv) haloalkoxyalkyl,

- (xvi) haloalkoxy,
- (xvii) alkoxyhaloalkyl,
- (xviii) alkylaminoalkyl,
- (xix) dialkylaminoalkyl,
- (xx) alkoxy, and

5



(xxi)

wherein z is 0-5 and  $R_{7a}$  is alkylene;

10  $R_{26}$  is (i) loweralkyl, (ii) haloalkyl, (iii) alkenyl, (iv) alkynyl, (v) cycloalkyl, (vi) cycloalkylalkyl, (vii) aryl, (viii) arylalkyl, (ix) heterocyclic, (x) (heterocyclic)alkyl, (xi) alkoxyalkyl or (xii) alkoxy-substituted haloalkyl; and  $R_{27}$  is alkylene or alkenylene;

15 (b)  $R_{22}-O-C(O)-R_{23}-$  wherein  $R_{22}$  is a carboxy protecting group or heterocyclic and  $R_{23}$  is (i) a covalent bond, (ii) alkylene, (iii) alkenylene or (iv)  $-N(R_{24})-R_{25}-$  wherein  $R_{25}$  is alkylene and  $R_{24}$  is hydrogen or loweralkyl,

- (c) loweralkyl,
- (d) alkenyl,
- (e) alkynyl,
- (f) cycloalkyl,
- (g) cycloalkylalkyl,
- (h) aryl,
- (i) arylalkyl,
- (j) aryloxyalkyl,
- (k) heterocyclic,
- (l) (heterocyclic)alkyl,
- (m) alkoxyalkyl,
- (n) alkoxyalkoxyalkyl, or
- (o)  $R_{13}-C(O)-CH(R_{14})-$

25 wherein  $R_{13}$  is amino, alkylamino or dialkylamino and  $R_{14}$  is aryl or  $R_{15}-C(O)-$  wherein  $R_{15}$  is amino, alkylamino or dialkylamino;

or a pharmaceutically acceptable salt thereof.

22. The compound according to Claim 21 wherein n is 0 and Z is -CH<sub>2</sub>-.

5 23. The compound according to Claim 21 wherein n is 1 and Z is -CH<sub>2</sub>-.

24. The compound according to Claim 21 wherein n is 0, Z is -CH<sub>2</sub>-, and R<sub>3</sub> is R<sub>4</sub>-C(O)-R<sub>5</sub>-, R<sub>6</sub>-SO<sub>2</sub>-R<sub>7</sub>- or R<sub>26</sub>-S(O)-R<sub>27</sub>- wherein R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>26</sub> and R<sub>27</sub> are as defined therein.

25. The compound according to Claim 21 wherein n is 0, Z is -CH<sub>2</sub>-, and R<sub>3</sub> is alkoxyalkyl or alkoxyalkoxyalkyl.

15 26. The compound according to Claim 21 wherein n is 0, Z is -CH<sub>2</sub>-, and R<sub>3</sub> is R<sub>4</sub>-C(O)-R<sub>5</sub>- wherein R<sub>4</sub> is (R<sub>11</sub>)(R<sub>12</sub>)N- as defined therein and R<sub>5</sub> is alkylene or R<sub>3</sub> is R<sub>6</sub>-S(O)<sub>2</sub>-R<sub>7</sub>- or R<sub>26</sub>-S(O)-R<sub>27</sub>- wherein R<sub>7</sub> is alkylene, R<sub>27</sub> is alkylene and R<sub>6</sub> and R<sub>26</sub> are as defined therein.

20 27. The compound according to Claim 21 wherein n is 0, Z is -CH<sub>2</sub>- and R<sub>3</sub> is R<sub>4</sub>-C(O)-N(R<sub>20</sub>)-R<sub>8</sub>- or R<sub>6</sub>-S(O)<sub>2</sub>-N(R<sub>21</sub>)-R<sub>10</sub>- wherein R<sub>8</sub> and R<sub>10</sub> are alkylene and R<sub>4</sub>, R<sub>6</sub>, R<sub>20</sub> and R<sub>21</sub> are as defined therein.

25 28. The compound according to Claim 21 wherein n is 0, R is tetrazolyl or -C(O)<sub>2</sub>-G wherein G is hydrogen or a carboxy protecting group or R is tetrazolyl or R is -C(O)-NHS(O)<sub>2</sub>R<sub>16</sub> wherein R<sub>16</sub> is loweralkyl, haloalkyl or aryl, Z is -CH<sub>2</sub>-, R<sub>1</sub> and R<sub>2</sub> are independently selected from (i) loweralkyl, (ii) cycloalkyl, (iii) substituted and unsubstituted aryl wherein aryl is phenyl substituted with one, two or three substituents independently selected from  
30 loweralkyl, alkoxy, halo, alkoxyalkoxy and carboxyalkoxy and (iv) substituted or unsubstituted heterocyclic, (v) alkenyl, (vi) heterocyclic (alkyl), (vii) aryloxyalkyl, (viii) aryalkyl, (ix) (N-alkanoyl-N-alkyl)aminoalkyl, and (x) alkylsulfonylamidoalkyl, and R<sub>3</sub> is R<sub>4</sub>-C(O)-R<sub>5</sub>- wherein R<sub>4</sub> is (R<sub>11</sub>)(R<sub>12</sub>)N- wherein R<sub>11</sub> and R<sub>12</sub> are independently selected  
35 from loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, heterocyclic, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, aryl and arylalkyl and R<sub>5</sub> is alkylene; or

R<sub>3</sub> is R<sub>4</sub>-C(O)-N(R<sub>20</sub>)-R<sub>8</sub>- or R<sub>6</sub>-S(O)<sub>2</sub>-N(R<sub>21</sub>)-R<sub>10</sub>-  
wherein R<sub>4</sub> is loweralkyl, aryl, alkoxy, alkylamino, aryloxy or arylalkoxy and  
R<sub>6</sub> is loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl,  
R<sub>8</sub> and R<sub>10</sub> are alkylene and R<sub>20</sub> and R<sub>21</sub> are loweralkyl; or

- 5 R<sub>3</sub> is R<sub>6</sub>-S(O)<sub>2</sub>-R<sub>7</sub>- or R<sub>26</sub>-S(O)-R<sub>27</sub>-  
wherein R<sub>6</sub> is loweralkyl or haloalkyl,  
R<sub>7</sub> is alkylene,  
R<sub>26</sub> is loweralkyl and  
R<sub>27</sub> is alkylene.

10

29. The compound according to Claim 21 wherein n is 0, R is  
-C(O)<sub>2</sub>-G wherein G is hydrogen or a carboxy protecting group, tetrazolyl or -  
C(O)-NHS(O)<sub>2</sub>R<sub>16</sub> wherein R<sub>16</sub> is loweralkyl, haloalkyl or aryl, Z is -CH<sub>2</sub>-, R<sub>1</sub> is (i)  
loweralkyl, (ii) alkenyl, (iii) alkoxyalkyl, (iv) cycloalkyl, (v) phenyl, (vi) pyridyl,  
15 (vii) furanyl or (viii) substituted or unsubstituted 4-methoxyphenyl, 4-  
fluorophenyl, 3-fluorophenyl, 4-ethoxyphenyl, 4-ethylphenyl, 4-methylphenyl,  
4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 3-fluoro-4-methoxyphenyl,  
3-fluoro-4-ethoxyphenyl, 2-fluorophenyl, 4-methoxymethoxyphenyl, 4-  
hydroxyphenyl, 4-*t*-butylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or  
20 dihydrobenzofuranyl wherein the substituent is selected from alkoxy,  
alkoxyalkoxy and carboxyalkoxy, (ix) arylalkyl, (x) aryloxyalkyl, (xi) heterocyclic  
(alkyl), (xii) (N-alkanoyl-N-alkyl)aminoalkyl, or (xiii) alkylsulfonylamidoalkyl, R<sub>2</sub> is  
substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl,  
1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl,  
25 benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or  
difluorophenyl and R<sub>3</sub> is R<sub>4</sub>-C(O)-N(R<sub>20</sub>)-R<sub>8</sub>- or R<sub>6</sub>-S(O)<sub>2</sub>-N(R<sub>21</sub>)-R<sub>10</sub>-  
wherein R<sub>8</sub> and R<sub>10</sub> are alkylene,

R<sub>20</sub> and R<sub>21</sub> are loweralkyl,

R<sub>4</sub> is loweralkyl, aryl, alkoxy, alkylamino, aryloxy or arylalkoxy and

- 30 R<sub>6</sub> is loweralkyl, haloalkyl, alkoxyalkyl, aryl or arylalkyl.

30. The compound according to Claim 21 wherein n is 0, R is  
-C(O)<sub>2</sub>-G wherein G is hydrogen or a carboxy protecting group, tetrazolyl or -  
C(O)-NHS(O)<sub>2</sub>R<sub>16</sub> wherein R<sub>16</sub> is loweralkyl, haloalkyl or aryl, Z is -CH<sub>2</sub>-, R<sub>1</sub> is (i)

- 35 loweralkyl, (ii) alkenyl, (iii) alkoxyalkyl, (iv) cycloalkyl, (v) phenyl, (vi) pyridyl,  
(vii) furanyl or (viii) substituted or unsubstituted 4-methoxyphenyl, 4-  
fluorophenyl, 3-fluorophenyl, 4-ethoxyphenyl, 4-ethylphenyl, 4-methylphenyl,



4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 3-fluoro-4-methoxyphenyl, 3-fluoro-4-ethoxyphenyl, 2-fluorophenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-*t*-butylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from alkoxy,

5 alkoxyalkoxy and carboxyalkoxy, (ix) aryalkyl, (x) aryoxyalkyl, (xi) heterocyclic (alkyl), (xii) (N-alkanoyl-N-alkyl)aminoalkyl, or (xiii) alkylsulfonylamidoalkyl,  $R_2$  is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or  
10 difluorophenyl and  $R_3$  is  $R_4-C(O)-R_5$  wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N-$  wherein  $R_{11}$  and  $R_{12}$  are independently selected from loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl and arylalkyl, heterocyclic, hydroxyalkyl, alkoxy, aminoalkyl, and trialkylaminoalkyl.

15 31. The compound according to Claim 21 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group, tetrazolyl or  $-C(O)-NHS(O)_2R_{16}$  wherein  $R_{16}$  is loweralkyl, haloalkyl or aryl,  $Z$  is  $-CH_2-$ ,  $R_1$  is (i) loweralkyl or (ii) alkenyl, (iii) aryalkyl, (iv) aryoxyalkyl, (v) heterocyclic (alkyl), (vi) aryl, (vii) (N-alkanoyl-N-alkyl)aminoalkyl, or (viii) alkylsulfonylamidoalkyl,  $R_2$   
20 is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the substituent is selected from loweralkyl, alkoxy and halogen and  $R_3$  is  $R_4-C(O)-R_5$  wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N-$   
25 wherein  $R_{11}$  is loweralkyl and  $R_{12}$  is aryl or arylalkyl.

32. The compound according to Claim 21 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group, tetrazolyl or  $-C(O)-NHS(O)_2R_{16}$  wherein  $R_{16}$  is loweralkyl, haloalkyl or aryl,  $Z$  is  $-CH_2-$ ,  $R_1$  is (i)  
30 phenyl or (ii) substituted or unsubstituted 4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 3-fluorophenyl, 3-fluoro-4-ethoxyphenyl, 2-fluorophenyl, 4-methoxymethoxyphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from loweralkyl, haloalkyl, alkoxy, alkoxyalkoxy and carboxyalkoxy,  $R_2$  is substituted or  
35 unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the

substituent is selected from loweralkyl, alkoxy and halogen and  $R_3$  is  $R_6-S(O)_2-N(R_{21})-R_{10}$ - wherein  $R_{10}$  is alkylene,  $R_6$  is loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl and  $R_{21}$  is loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl.

5

33 The compound according to Claim 21 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group, tetrazolyl or  $-C(O)-NHS(O)_2R_{16}$  wherein  $R_{16}$  is loweralkyl, haloalkyl or aryl,  $Z$  is  $-CH_2-$ ,  $R_1$  is substituted or unsubstituted 4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 3-fluorophenyl, 3-fluoro-4-ethoxyphenyl, 4-methoxymethoxyphenyl, 1,3-benzodioxolyl or 1,4-benzodioxanyl wherein the substituent is selected from loweralkyl, haloalkyl, alkoxy and alkoxyalkoxy,  $R_2$  is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the substituent is selected from loweralkyl, alkoxy and halogen and  $R_3$  is alkoxycarbonyl or  $R_6-S(O)_2-N(R_{21})-R_{10}$ - wherein  $R_{10}$  is alkylene,  $R_6$  is loweralkyl, haloalkyl, alkoxyalkyl or haloalkoxyalkyl and  $R_{21}$  is loweralkyl, haloalkyl, alkoxyalkyl or haloalkoxyalkyl.

10

15

20

34. The compound according to Claim 21 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group, tetrazolyl or  $-C(O)-NHS(O)_2R_{16}$  wherein  $R_{16}$  is loweralkyl or haloalkyl,  $Z$  is  $-CH_2-$ ,  $R_1$  is substituted or unsubstituted 4-methoxyphenyl, 4-fluorophenyl, 2-fluorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-ethylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from alkoxy, alkoxyalkoxy and carboxyalkoxy,  $R_2$  is 1,3-benzodioxolyl, 1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl and  $R_3$  is  $R_4-C(O)-R_5$ - wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N$ - wherein  $R_{11}$  and  $R_{12}$  are independently selected from loweralkyl, aryl arylalkyl, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, and heterocyclic.

25

30

35

35. The compound according to Claim 21 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group, tetrazolyl or  $-C(O)-NHS(O)_2R_{16}$  wherein  $R_{16}$  is loweralkyl or haloalkyl,  $Z$  is  $-CH_2-$ ,  $R_1$  is

loweralkyl, alkoxyalkyl or alkenyl,  $R_2$  is 1,3-benzodioxolyl, 1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl and  $R_3$  is  $R_4-C(O)-R_5-$  wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N-$  wherein  $R_{11}$  and  $R_{12}$  are independently selected from loweralkyl, aryl, arylalkyl, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, and heterocyclic.

36. The compound according to Claim 21 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group,  $Z$  is  $-CH_2-$ ,  $R_1$  is substituted or unsubstituted 4-methoxyphenyl, 4-fluorophenyl, 2-fluorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-ethylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from alkoxy, alkoxyalkoxy and carboxyalkoxy,  $R_2$  is 1,3-benzodioxolyl, 1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl and  $R_3$  is  $R_4-C(O)-R_5-$  wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N-$  wherein  $R_{11}$  and  $R_{12}$  are independently selected from loweralkyl.

37. The compound according to Claim 21 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group,  $Z$  is  $-CH_2-$ ,  $R_1$  is substituted or unsubstituted 4-methoxyphenyl, 4-fluorophenyl, 2-fluorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-ethylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from alkoxy, alkoxyalkoxy and carboxyalkoxy,  $R_2$  is 1,3-benzodioxolyl, 1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl and  $R_3$  is  $R_4-C(O)-R_5-$  wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N-$  wherein  $R_{11}$  is loweralkyl and  $R_{12}$  is aryl.

38. The compound according to Claim 21 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group,  $Z$  is  $-CH_2-$ ,  $R_1$  is substituted or unsubstituted 4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 3-fluorophenyl, 2-fluorophenyl, 3-fluoro-4-ethoxyphenyl, 4-methoxymethoxyphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or

dihydrobenzofuranyl wherein the substituent is selected from loweralkyl, haloalkyl, alkoxy, alkoxyalkoxy and carboxyalkoxy,  $R_2$  is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the substituent is selected from loweralkyl, alkoxy and halogen and  $R_3$  is  $R_6-S(O)_2-N(R_{21})-R_{10}$ - wherein  $R_{10}$  is alkylene,  $R_6$  is loweralkyl, haloalkyl, alkoxyalkyl or haloalkoxyalkyl and  $R_{21}$  is loweralkyl, haloalkyl or alkoxyalkyl.

39. The compound according to Claim 21 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group,  $Z$  is  $-CH_2-$ ,  $R_1$  is loweralkyl, alkenyl, heterocyclic (alkyl), aryloxyalkyl, aryalkyl, aryl, (N-alkanoyl-N-alkyl)aminoalkyl, or alkylsulfonylamidoalkyl, and  $R_3$  is  $R_4-C(O)-R_5$ - wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N$ - wherein  $R_{11}$  and  $R_{12}$  are independently selected from alkyl, aryl, hydroxyalkyl, alkoxy, aminoalkyl, and heterocyclic.

40. A compound according to Claim 21 wherein  $n$  is 0,  $R$  is  $-C(O)_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group,  $Z$  is  $-CH_2-$ ,  $R_1$  is loweralkyl, alkenyl, heterocyclic (alkyl), aryloxyalkyl, aryalkyl, aryl, (N-alkanoyl-N-alkyl)aminoalkyl, or alkylsulfonylamidoalkyl, and  $R_3$  is  $R_4-C(O)-R_5$ - wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N$ - wherein  $R_{11}$  and  $R_{12}$  are independently selected from alkyl, aryl, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, and heterocyclic, with the proviso that one or  $R_{11}$  and  $R_{12}$  is alkyl

41. A compound selected from the group consisting of  
*trans-trans*-2-(4-Methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(3-(N-propyl-N-*n*-pentanesulfonylamino)propyl)-pyrrolidine-3-carboxylic acid;  
*trans, trans*-2-(4-Methoxymethoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-*n*-pentanesulfonylamino)ethyl)pyrrolidine-3-carboxylic acid;  
*trans, trans*-2-(3,4-Dimethoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-*n*-pentanesulfonylamino)ethyl)pyrrolidine-3-carboxylic acid;  
*trans, trans*-2-(3,4-Dimethoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-*n*-hexanesulfonylamino)ethyl)pyrrolidine-3-carboxylic acid;  
*trans, trans*-2-(4-Propoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-*n*-pentanesulfonylamino)ethyl)pyrrolidine-3-carboxylic acid;

- trans,trans*-2-(3,4-Difluorophenyl)-4-(1,3-benzodioxol-5-yl)-1-(((N,N-di(*n*-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;
- trans,trans*-2-(3,4-Difluorophenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-*n*-pentanesulfonylamino)ethyl)pyrrolidine-3-carboxylic acid;
- 5 *trans,trans*-2-(3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-*n*-hexanesulfonylamino)ethyl)pyrrolidine-3-carboxylic acid;
- trans,trans*-2-(3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-(3-chloropropanesulfonyl)amino)ethyl)-pyrrolidine-3-carboxylic acid;
- 10 *trans,trans*-2-(3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-isobutyl-N-(3-chloropropanesulfonyl)amino)ethyl)pyrrolidine-3-carboxylic acid;
- trans,trans*-2-(3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-(4-methylbutanesulfonyl)amino)ethyl)pyrrolidine-3-carboxylic acid;
- 15 *trans,trans*-2-(4-Methoxy-3-fluorophenyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-(*n*-pentanesulfonyl)amino)ethyl)pyrrolidine-3-carboxylic acid;
- trans,trans*-2-(3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-(2,2,3,3,3-pentafluoropropoxyethanesulfonyl)-amino)ethyl)pyrrolidine-3-carboxylic acid;
- 20 *trans,trans*-2-(1,4-Benzodioxan-6-yl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-(*n*-pentanesulfonyl)amino)ethyl)pyrrolidine-3-carboxylic acid;
- 25 *trans,trans*-2-(3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-isobutyl-N-(pentanesulfonylamino)ethyl)pyrrolidine-3-carboxylic acid;
- trans,trans*-2-(3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-(2-methoxyethyl)-N-(3-chloropropanesulfonyl)amino)-ethyl)pyrrolidine-3-carboxylic acid;
- 30 *trans,trans*-2-(3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-(2-methoxyethyl)-N-(pentanesulfonyl)amino)ethyl)pyrrolidine-3-carboxylic acid;
- trans,trans*-2-(3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-((2,2,2-trifluoroethoxyethane)sulfonyl)amino)-ethyl)pyrrolidine-
- 35 3-carboxylic acid;

*trans,trans*-2-(3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-(2-methoxyethyl)-N-(butanesulfonylamino)ethyl)-pyrrolidine-3-carboxylic acid;

5 *trans,trans*-2-(3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-(2-methylpropanesulfonyl)amino)ethyl)pyrrolidine-3-carboxylic acid; and

*trans,trans*-2-(3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-isobutyl-N-(butanesulfonylamino))ethyl)pyrrolidine-3-carboxylic acid;

10 *trans,trans*-2-(2-Methylpentyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;

*trans,trans*-2-(2,2-Dimethylpentyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;

*trans,trans*-2-(2-(1,3-Dioxo-2-yl)ethyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;

15 *trans,trans*-2-(2-(2-Tetrahydro-2H-pyran)ethyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;

*trans,trans*-2-(2,2,4-Trimethyl-3-pentenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;

20 *trans,trans*-2-(2,2-Dimethyl-2-(1,3-dioxolan-2-yl)ethyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;

*trans,trans*-2-(2-(1,3-Dioxo-2-yl)ethyl)-4-(1,3-benzodioxol-5-yl)-1-((N-4-heptyl-N-(2-methyl-3-fluorophenyl))aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;

25 *trans,trans*-2-(2-(1,3-Dioxol-2-yl)ethyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid

*trans,trans*-2-((2-Methoxyphenoxy)-methyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;

30 (2*S*,3*R*,4*S*)-2-(2,2-Dimethylpentyl)-4-(1,3-benzodioxol-5-yl)-1-(N-4-heptyl-N-(4-fluoro-3-methylphenyl))aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;

*trans,trans*-2-(2-(2-Oxopyrrolidin-1-yl)ethyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;

(2*S*,3*R*,4*S*)-2-(2,2-Dimethylpentyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid

35 *trans,trans*-2-(2-(1,3-Dioxol-2-yl)ethyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(N-4-heptyl-N-(4-fluoro-3-methylphenyl))aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;

- trans,trans*-2-(2,2-Dimethylpentyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;
- trans,trans*-2-(2,2-dimethylpentyl)-4-(2,3-dihydro-benzofuran-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;
- 5 *trans,trans*-2-(2,2,-Dimethyl-2-(1,3-dioxolan-2-yl)ethyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;
- trans,trans*-2-(2-(2-Methoxyphenyl)-ethyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;
- 10 *trans,trans*-2-(2,2-Dimethyl-3-(E)-pentenyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;
- trans,trans*-2-(2-(2-pyridyl)ethyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;
- (2*S*, 3*R*, 4*S*)-2-(2-(2-oxopyrrolidin-1-yl)ethyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;
- 15 (2*S*, 3*R*, 4*S*)-2-(2-(2-oxopyrrolidin-1-yl)ethyl)-4-(1,3-benzodioxol-5-yl)-1-(N-4-heptyl-N-(4-fluoro-3-methylphenyl))aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;
- trans,trans*-2-(2-(1-pyrazolyl)ethyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;
- 20 *trans,trans*-2-(4-Methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-((N-butyl-N-(4-dimethylaminobutyl)amino)carbonylmethyl)-pyrrolidine-3-carboxylic acid;
- (2*R*,3*R*,4*S*)-2-(3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-pentanesulfonylamino)ethyl)-pyrrolidine-3-carboxylic acid;
- 25 (2*S*,3*R*,4*S*)-2-(2,2-Dimethylpentyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;
- (2*S*,3*R*,4*S*)-2-(2,2-Dimethylpent-(E)-3-enyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;
- 30 (2*S*,3*R*,4*S*)-2-(2,2-Dimethylpent-(E)-3-enyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid;
- (2*S*,3*R*,4*S*)-2-((2-Methoxyphenoxy)-methyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid;
- (2*S*,3*R*,4*S*)-2-(2-(2-Methoxyphenyl)ethyl)-4(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid;
- 35 *trans,trans*-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N-((bis-(o-tolyl)methyl)amino)carbonylmethyl)-( pyrrolidine-3-carboxylic acid;

*trans,trans*-2-[4-(2-methoxyethoxy)phenyl]-4-(1,3-benzodioxol-5-yl)-1-(N-(2,2-dimethyl-1-phenylpropyl)-1-amino)carbonylmethyl)-pyrrolidine-3-carboxylic acid;

*trans,trans*-2-[4-(2-methoxyethoxy)phenyl]-4-(1,3-benzodioxol-5-yl)-1-(N-((bis-(o-tolyl)methyl)amino)carbonylmethyl)-pyrrolidine-3-carboxylic acid;

5 *trans,trans*-2-[4-(2-isopropoxyethoxy)phenyl]-4-(1,3-benzodioxol-5-yl)-1-(N-(2,2-dimethyl-1-phenylpropyl)-1-amino)carbonylmethyl)-pyrrolidine-3-carboxylic acid;


*trans,trans*-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N-(3,3-dimethyl-1-phenylbutyl)-1-amino)carbonylmethyl)-pyrrolidine-3-carboxylic acid;

10 *trans,trans*-2-[4-(2-isopropoxyethoxy)phenyl]-4-(1,3-benzodioxol-5-yl)-1-(N-((1-(o-tolyl)-1-(o-ethylphenyl)-methyl)amino)carbonylmethyl)-pyrrolidine-3-carboxylic acid;

*trans,trans*-2-(4-(2-(2-propoxy)ethoxy)phenyl)-4-(1,3-benzodioxol-5-yl)-1-N-phenyl-N-t-butylhydrazino carbonylmethyl)-pyrrolidine-3-carboxylic acid; and

15 *trans,trans*-2-(4-(2-methoxyethoxy)phenyl)-4-(1,3-benzodioxol-5-yl)-1-(N-phenyl-N-t-butylhydrazino carbonylmethyl)-pyrrolidine-3-carboxylic acid;  
or a pharmaceutically acceptable salt thereof.

42. A compound of the formula:



20 wherein n is 0 or 1;

m is 0 to 6;

W is (a) -C(O)<sub>2</sub>-G where G is hydrogen or a carboxy protecting group, (b) -PO<sub>3</sub>H<sub>2</sub>,

25 (c) -P(O)(OH)E where E is hydrogen, loweralkyl or arylalkyl,

(d) -CN,

(e) -C(O)NHR<sub>17</sub> where R<sub>17</sub> is loweralkyl,

(f) alkylaminocarbonyl,

(g) dialkylaminocarbonyl,

30 (h) tetrazolyl,

(i) hydroxy,


(j) alkoxy,

(k) sulfonamido,




(l)  $-C(O)NHS(O)_2R_{16}$  where  $R_{16}$  is loweralkyl, haloalkyl, phenyl or dialkylamino,


(m)  $-S(O)_2NHC(O)R_{16}$ .




(n)




(o)




(p)




(q)



(r)




(s)



(t)

, or



(u)

; and


$R_1$  and  $R_2$  are independently selected from hydrogen, loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl,

alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl and  $(R_{aa})(R_{bb})N-R_{cc}$ - wherein  $R_{aa}$  is aryl or arylalkyl,  $R_{bb}$  is hydrogen or alkanoyl and  $R_{cc}$  is alkylene, with the proviso that one or both of  $R_1$  and  $R_2$  is other than hydrogen; or a salt thereof.

43. The compound of Claim 42 wherein  $m$  is zero or 1;  $W$  is  $-CO_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group; or the substantially pure (+)- or (-)-isomer thereof.

44. The compound of Claim 42 wherein  $n$  and  $m$  are both 0;  $W$  is  $-CO_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group; and  $R_1$  is (i) loweralkyl, (ii) alkenyl, (iii) alkoxyalkyl, (iv) cycloalkyl, (v) phenyl, (vi) pyridyl, (vii) furanyl or (viii) substituted or unsubstituted 4-methoxyphenyl, 4-fluorophenyl, 3-fluorophenyl, 4-ethoxyphenyl, 4-ethylphenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 3-fluoro-4-methoxyphenyl, 3-fluoro-4-ethoxyphenyl, 2-fluorophenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-*t*-butylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from loweralkyl, haloalkyl, alkoxy, alkoxyalkoxy and carboxyalkoxy, (ix) arylalkyl, (x) aryloxyalkyl, (xi) heterocyclic (alkyl), (xii) (N-alkanoyl-N-alkyl)aminoalkyl, or (xiii) alkylsulfonylamidoalkyl, and  $R_2$  is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the substituent is selected from loweralkyl, alkoxy and halogen; or the substantially pure (+)- or (-)-isomer thereof.

45. The compound according to Claim 42 of the formula:



wherein n is 0 or 1;

m is 0 to 6;

5 W is (a)  $-C(O)_2-G$  where G is hydrogen or a carboxy protecting group, (b)  $-PO_3H_2$ ,

(c)  $-P(O)(OH)E$  where E is hydrogen, loweralkyl or arylalkyl,

(d)  $-CN$ ,

(e)  $-C(O)NHR_{17}$  where  $R_{17}$  is loweralkyl,

(f) alkylaminocarbonyl,

(g) dialkylaminocarbonyl,

(h) tetrazolyl,




(i) hydroxy,


(j) alkoxy,

(k) sulfonamido,

(l)  $-C(O)NHS(O)_2R_{16}$  where  $R_{16}$  is loweralkyl, haloalkyl, phenyl or dialkylamino,

(m)  $-S(O)_2NHC(O)R_{16}$ .





R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen, loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy carbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl and (R<sub>aa</sub>)(R<sub>bb</sub>)N-R<sub>cc</sub>- wherein R<sub>aa</sub> is aryl or arylalkyl, R<sub>bb</sub> is hydrogen or alkanoyl and R<sub>cc</sub> is alkylene, with the proviso that one or both of R<sub>1</sub> and R<sub>2</sub> is other than hydrogen; or a salt thereof.

46. The compound according to Claim 45 wherein m is zero or 1; W is -CO<sub>2</sub>-G wherein G is hydrogen or a carboxy protecting group; or the substantially pure (+)- or (-)-isomer thereof.


47. The compound according to Claim 45 wherein n and m are both 0;

W is -CO<sub>2</sub>-G wherein G is hydrogen or a carboxy protecting group;  
and R<sub>1</sub> is (i) loweralkyl, (ii) alkenyl, (iii) alkoxyalkyl, (iv) cycloalkyl, (v) phenyl,  
(vi) pyridyl, (vii) furanyl or (viii) substituted or unsubstituted 4-methoxyphenyl,  
4-fluorophenyl, 3-fluorophenyl, 4-ethoxyphenyl, 4-ethylphenyl, 4-  
5 methylphenyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 3-fluoro-4-  
methoxyphenyl, 3-fluoro-4-ethoxyphenyl, 2-fluorophenyl, 4-  
methoxymethoxyphenyl, 4-hydroxyphenyl, 4-*t*-butylphenyl, 1,3-benzodioxolyl,  
1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected  
from loweralkyl, haloalkyl, alkoxy, alkoxyalkoxy and carboxyalkoxy, (ix)  
10 aryalkyl, (x) aryloxyalkyl, (xi) heterocyclic (alkyl), (xii) (N-alkanoyl-N-  
alkyl)aminoalkyl, or (xiii) alkylsulfonylamidoalkyl, and R<sub>2</sub> is substituted or  
unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-  
benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl,  
benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or  
15 difluorophenyl wherein the substituent is selected from loweralkyl, alkoxy and  
halogen; or  
the substantially pure (+)- or (-)-isomer thereof.

48. The substantially pure compound (+)-trans,trans-2-(4-  
20 Methoxyphenyl)-4-(1,3-benzodioxo-5-yl)pyrrolidine-3-carboxylic acid; or a salt  
or ester thereof.

49. The substantially pure compound (2*S*,3*R*,4*S*)-2-(2,2-  
Dimethylpentyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(N,N-di(*n*-  
25 butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid; or a salt or ester  
thereof.

50. A compound of the formula



5 wherein n is 0 or 1;

m is 0 to 6;

R<sub>5b</sub> is alkylene;

Q is a leaving group;

W is (a) -C(O)<sub>2</sub>-G where G is hydrogen or a carboxy protecting group, (b)

10 -PO<sub>3</sub>H<sub>2</sub>,

(c) -P(O)(OH)E where E is hydrogen, loweralkyl or arylalkyl,

(d) -CN,

(e) -C(O)NHR<sub>17</sub> where R<sub>17</sub> is loweralkyl,

(f) alkylaminocarbonyl,

15 (g) dialkylaminocarbonyl,

(h) tetrazolyl,


(i) hydroxy,

(j) alkoxy,


(k) sulfonamido,

20 (l) -C(O)NHS(O)<sub>2</sub>R<sub>16</sub> where R<sub>16</sub> is loweralkyl, haloalkyl, phenyl or







dialkylamino,  
(m) -S(O)<sub>2</sub>NHC(O)R<sub>16</sub>.



(n)



(o)



R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen, loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy carbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl and (R<sub>aa</sub>)(R<sub>bb</sub>)N-R<sub>cc</sub>- wherein R<sub>aa</sub> is aryl or arylalkyl, R<sub>bb</sub> is hydrogen or alkanoyl and R<sub>cc</sub> is alkylene, with the proviso that one or both of R<sub>1</sub> and R<sub>2</sub> is other than hydrogen; or a salt thereof.

51. The compound according to Claim 50 wherein

m is zero or 1;

R<sub>5b</sub> is alkylene;

Q is a leaving group; and

- 5 W is -CO<sub>2</sub>-G wherein G is hydrogen or a carboxy protecting group; or the substantially pure (+)- or (-)-isomer thereof.

52. The compound according to Claim 50 wherein

n and m are both 0;

10 R<sub>5b</sub> is alkylene;

Q is a leaving group;

W is -CO<sub>2</sub>-G wherein G is hydrogen or a carboxy protecting group;

and R<sub>1</sub> is (i) loweralkyl, (ii) alkenyl, (iii) alkoxyalkyl, (iv) cycloalkyl, (v) phenyl, (vi) pyridyl, (vii) furanyl or (viii) substituted or unsubstituted 4-methoxyphenyl, 4-fluorophenyl, 3-fluorophenyl, 4-ethoxyphenyl, 4-ethylphenyl, 4-


15 methylphenyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 3-fluoro-4-methoxyphenyl, 3-fluoro-4-ethoxyphenyl, 2-fluorophenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-t-butylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from loweralkyl, haloalkyl, alkoxy, alkoxyalkoxy and carboxyalkoxy and R<sub>2</sub> is

20 substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the substituent is selected from loweralkyl, alkoxy and

25 halogen, (ix) aryalkyl, (x) aryloxyalkyl, (xi) heterocyclic (alkyl), (xii) (N-alkanoyl-N-alkyl)aminoalkyl, or (xiii) alkysulfonylamidoalkyl; or the substantially pure (+)- or (-)-isomer thereof.

53. The compound according to Claim 50 of the formula

30



wherein n is 0 or 1;



m is 0 to 6;

R<sub>5b</sub> is alkylene;

Q is a leaving group;

W is (a) -C(O)<sub>2</sub>-G where G is hydrogen or a carboxy protecting group, (b)

5 -PO<sub>3</sub>H<sub>2</sub>,

(c) -P(O)(OH)E where E is hydrogen, loweralkyl or arylalkyl,

(d) -CN,

(e) -C(O)NHR<sub>17</sub> where R<sub>17</sub> is loweralkyl,

(f) alkylaminocarbonyl,

10 (g) dialkylaminocarbonyl,

(h) tetrazolyl,


(i) hydroxy,

(j) alkoxy,


(k) sulfonamido,

15 (l) -C(O)NHS(O)<sub>2</sub>R<sub>16</sub> where R<sub>16</sub> is loweralkyl, haloalkyl, phenyl or dialkylamino,


(m) -S(O)<sub>2</sub>NHC(O)R<sub>16</sub>.




(n)




(o)



(p)






(q)



(r)

20



; and

R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen, loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonamidoalkyl, heterocyclic, (heterocyclic)alkyl and (R<sub>aa</sub>)(R<sub>bb</sub>)N-R<sub>cc</sub>- wherein R<sub>aa</sub> is aryl or arylalkyl, R<sub>bb</sub> is hydrogen or alkanoyl and R<sub>cc</sub> is alkylene, with the proviso that one or both of R<sub>1</sub> and R<sub>2</sub> is other than hydrogen; or a salt thereof.

54. The compound according to Claim 53 wherein m is zero or 1; R<sub>5b</sub> is alkylene; Q is a leaving group; W is -CO<sub>2</sub>-G wherein G is hydrogen or a carboxy protecting group; or the substantially pure (+)- or (-)-isomer thereof.

55. The compound according to Claim 53 wherein n and m are both 0; R<sub>5b</sub> is alkylene; Q is a leaving group; W is -CO<sub>2</sub>-G wherein G is hydrogen or a carboxy protecting group; and R<sub>1</sub> is (i) loweralkyl, (ii) alkenyl, (iii) alkoxyalkyl, (iv) cycloalkyl, (v) phenyl, (vi) pyridyl, (vii) furanyl or (viii) substituted or unsubstituted 4-methoxyphenyl, 4-fluorophenyl, 3-fluorophenyl, 4-ethoxyphenyl, 4-ethylphenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 3-fluoro-4-methoxyphenyl, 3-fluoro-4-ethoxyphenyl, 2-fluorophenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-t-butylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from loweralkyl, haloalkyl, alkoxy, alkoxyalkoxy and carboxyalkoxy and R<sub>2</sub> is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl,

1. The first part of the report discusses the importance of maintaining accurate records of all transactions, including sales, purchases, and expenses. It emphasizes the need for consistency and transparency in financial reporting.


2. The second part of the report provides a detailed analysis of the company's financial performance over the past year. It includes a comparison of actual results with budgeted figures and identifies areas where the company has exceeded expectations.

3. The third part of the report outlines the company's financial goals for the upcoming year. It includes a discussion of the strategies that will be implemented to achieve these goals and a timeline for implementation.

4. The fourth part of the report discusses the company's financial risks and the measures that will be taken to mitigate them. It includes a discussion of the company's credit policy and its approach to managing debt.

5. The fifth part of the report provides a summary of the company's financial position and a conclusion. It includes a statement of the company's confidence in its financial future and a commitment to transparency and accountability.

56. A compound of the formula



5 wherein n is 0 or 1; m is 0 to 6; R<sub>5b</sub> is alkylene;

R<sub>20a</sub> is hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl;

W is (a) -C(O)<sub>2</sub>-G where G is hydrogen or a carboxy protecting group, (b) -PO<sub>3</sub>H<sub>2</sub>,

(c) -P(O)(OH)E where E is hydrogen, loweralkyl or arylalkyl,

(d) -CN,

(e) -C(O)NHR<sub>17</sub> where R<sub>17</sub> is loweralkyl,

(f) alkylaminocarbonyl,

(g) dialkylaminocarbonyl,

(h) tetrazolyl,


(i) hydroxy,

(j) alkoxy,


(k) sulfonamido,

(l) -C(O)NHS(O)<sub>2</sub>R<sub>16</sub> where R<sub>16</sub> is loweralkyl, haloalkyl, phenyl or dialkylamino,


(m) -S(O)<sub>2</sub>NHC(O)R<sub>16</sub>,








(n)



(o)



(p)



$R_1$  and  $R_2$  are independently selected from hydrogen, loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl and  $(R_{aa})(R_{bb})N-R_{cc}$  - wherein  $R_{aa}$  is aryl or arylalkyl,  $R_{bb}$  is hydrogen or alkanoyl and  $R_{cc}$  is alkylene, with the proviso that one or both of  $R_1$  and  $R_2$  is other than hydrogen; or a salt thereof.

57. The compound according to Claim 56 wherein  
 $m$  is zero or 1;  
 $R_{5b}$  is alkylene;  
 $R_{20a}$  is hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl; and  
 $W$  is  $-CO_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group; or the substantially pure (+)- or (-)-isomer thereof.

58. The compound according to Claim 56 wherein

n and m are both 0;

R<sub>5b</sub> is alkylene;

R<sub>20a</sub> is hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl,

5 cycloalkyl, cycloalkylalkyl, aryl or arylalkyl;

W is -CO<sub>2</sub>-G wherein G is hydrogen or a carboxy protecting group;

and R<sub>1</sub> is (i) loweralkyl, (ii) alkenyl, (iii) alkoxyalkyl, (iv) cycloalkyl, (v) phenyl, (vi)

pyridyl, (vii) furanyl or (viii) substituted or unsubstituted 4-methoxyphenyl, 4-

fluorophenyl, 3-fluorophenyl, 4-ethoxyphenyl, 4-ethylphenyl, 4-methylphenyl, 4-

10 trifluoromethylphenyl, 4-pentafluoroethylphenyl, 3-fluoro-4-methoxyphenyl, 3-fluoro-

4-ethoxyphenyl, 2-fluorophenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-t-

butylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein

the substituent is selected from loweralkyl, haloalkyl, alkoxy, alkoxyalkoxy and

carboxyalkoxy, (ix) arylalkyl, (x) aryloxyalkyl, (xi) heterocyclic (alkyl), (xii) (N-alkanoyl-

15 N-alkyl)aminoalkyl, or (xiii) alkylsulfonylamidoalkyl, and R<sub>2</sub> is substituted or

unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-


methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl,

dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the substituent is selected

from loweralkyl, alkoxy and halogen; or

20 the substantially pure (+)- or (-)-isomer thereof.

59. The compound according to Claim 56 of the formula



25 wherein n is 0 or 1; m is 0 to 6; R<sub>5b</sub> is alkylene; R<sub>20a</sub> is hydrogen, loweralkyl, alkenyl,

haloalkyl, alkoxyalkyl, haloalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl;

W is (a) -C(O)<sub>2</sub>-G where G is hydrogen or a carboxy protecting group, (b)

-PO<sub>3</sub>H<sub>2</sub>,









30 (c) -P(O)(OH)E where E is hydrogen, loweralkyl or arylalkyl,

(d) -CN,

(e) -C(O)NHR<sub>17</sub> where R<sub>17</sub> is loweralkyl,

(f) alkylaminocarbonyl,

- (g) dialkylaminocarbonyl,  
 (h) tetrazolyl,  
 (i) hydroxy,  
 (j) alkoxy,  
 5 (k) sulfonamido,  
 (l)  $-C(O)NHS(O)_2R_{16}$  where  $R_{16}$  is loweralkyl, haloalkyl, phenyl or dialkylamino,  
 (m)  $-S(O)_2NHC(O)R_{16}$ .



$R_1$  and  $R_2$  are independently selected from hydrogen, loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl and  $(R_{aa})(R_{bb})N-R_{cc}$ - wherein  $R_{aa}$  is aryl or arylalkyl,  $R_{bb}$  is hydrogen or alkanoyl and  $R_{cc}$  is alkylene, with the proviso that one or both of  $R_1$  and  $R_2$  is other than hydrogen; or a salt thereof.

60. The compound according to Claim 59 wherein

$m$  is zero or 1;

$R_{5b}$  is alkylene;

$R_{20a}$  is hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl; and  $W$  is  $-CO_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group; or the substantially pure (+)- or (-)-isomer thereof.

61. The compound according to Claim 58 wherein

$n$  and  $m$  are both 0;  $R_{5b}$  is alkylene;  $R_{20a}$  is hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl;  $W$  is  $-CO_2-G$  wherein  $G$  is hydrogen or a carboxy protecting group; and  $R_1$  is (i) loweralkyl, (ii) alkenyl, (iii) alkoxyalkyl, (iv) cycloalkyl, (v) phenyl, (vi) pyridyl, (vii) furanyl or (viii) substituted or unsubstituted 4-methoxyphenyl, 4-fluorophenyl, 3-fluorophenyl, 4-ethoxyphenyl, 4-ethylphenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 3-fluoro-4-methoxyphenyl, 3-fluoro-4-ethoxyphenyl, 2-fluorophenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-*t*-butylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from loweralkyl, haloalkyl, alkoxy, alkoxyalkoxy and carboxyalkoxy, (ix) arylalkyl, (x) aryloxyalkyl, (xi) heterocyclic (alkyl), (xii) (N-alkanoyl-N-alkyl)aminoalkyl, or (xiii) alkylsulfonylamidoalkyl, and  $R_2$  is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the substituent is selected from loweralkyl, alkoxy and halogen; or the substantially pure (+)- or (-)-isomer thereof.



62. A pharmaceutical composition for antagonizing the action of endothelin comprising a therapeutically effective amount of the compound of Claim 1 and a pharmaceutically acceptable carrier.

5

63. A pharmaceutical composition for antagonizing the action of endothelin comprising a therapeutically effective amount of the compound of Claim 21 and a pharmaceutically acceptable carrier.

10

64. A pharmaceutical composition for antagonizing the action of endothelin comprising a therapeutically effective amount of (2*S*,3*R*,4*S*)-2-(2,2-Dimethylpentyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(*N,N*-di(*n*-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid and a pharmaceutically acceptable carrier.

15

65. A pharmaceutical composition for antagonizing the action of endothelin comprising a therapeutically effective amount of (2*S*,3*R*,4*S*)-2-3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(*N*-propyl-*N*-pentanesulfonyl)ethyl)-pyrrolidine-3-carboxylic acid and a pharmaceutically acceptable carrier.

20

66. A method for antagonizing the action of endothelin comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

25

67. A method for antagonizing the action of endothelin comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 21.

30

68. A method for antagonizing the action of endothelin comprising administering to a mammal in need of such treatment a therapeutically effective amount of (2*S*,3*R*,4*S*)-2-(2,2-Dimethylpentyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(*N,N*-di(*n*-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid.

35

69. A method for antagonizing the action of endothelin comprising administering to a mammal in need of such treatment a therapeutically effective amount of (2*S*,3*R*,4*S*)-2-3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(*N*-propyl-*N*-pentanesulfonyl)ethyl)-pyrrolidine-3-carboxylic acid.

70. A method for treating hypertension, congestive heart failure, restenosis following arterial injury, renal failure, cancer, colitis, reperfusion injury, angina, pulmonary hypertension, migraine, cerebral or myocardial ischemia or atherosclerosis comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

71. A method for treating coronary angina, cerebral vasospasm, acute and chronic renal failure, gastric ulceration, cyclosporin-induced nephrotoxicity, endotoxin-induced toxicity, asthma, LPL-related lipoprotein disorders, proliferative diseases, acute or chronic pulmonary hypertension, platelet aggregation, thrombosis, IL-2 mediated cardiotoxicity, nociception, colitis, vascular permeability disorders, ischemia-reperfusion injury, raynaud's disease and migraine comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1.

72. A method for treating hypertension, congestive heart failure, restenosis following arterial injury, renal failure, cancer, colitis, reperfusion injury, angina, pulmonary hypertension, migraine, cerebral or myocardial ischemia or atherosclerosis comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 21.

73. A method for treating hypertension, congestive heart failure, restenosis following arterial injury, renal failure, cancer, colitis, reperfusion injury, angina, pulmonary hypertension, migraine, cerebral or myocardial ischemia or atherosclerosis comprising administering to a mammal in need of such treatment a therapeutically effective amount of (2*S*,3*R*,4*S*)-2-(2,2-Dimethylpentyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(*N,N*-di(*n*-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid.

74. A method for treating hypertension, congestive heart failure, restenosis following arterial injury, renal failure, cancer, colitis, reperfusion injury, angina, pulmonary hypertension, migraine, cerebral or myocardial ischemia or atherosclerosis comprising administering to a mammal in need of such treatment a therapeutically effective amount of (2*S*,3*R*,4*S*)-2-3-Fluoro-4-methoxyphenyl)-4-(1,3-

benzodioxol-5-yl)-1-(2-(N-propyl-N-pentanesulfonyl)ethyl)-pyrrolidine-3-carboxylic acid.

5           75.    A method for treating coronary angina, cerebral vasospasm, acute and chronic renal failure, gastric ulceration, cyclosporin-induced nephrotoxicity, endotoxin-induced toxicity, asthma, LPL-related lipoprotein disorders, proliferative diseases, acute or chronic pulmonary hypertension, platelet aggregation, thrombosis, IL-2 mediated cardiotoxicity, nociception, colitis, vascular permeability disorders, ischemia-reperfusion injury, raynaud's disease and migraine comprising  
10 administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 21.

15           76.    A method for treating coronary angina, cerebral vasospasm, acute and chronic renal failure, gastric ulceration, cyclosporin-induced nephrotoxicity, endotoxin-induced toxicity, asthma, LPL-related lipoprotein disorders, proliferative diseases, acute or chronic pulmonary hypertension, platelet aggregation, thrombosis, IL-2 mediated cardiotoxicity, nociception, colitis, vascular permeability disorders, ischemia-reperfusion injury, raynaud's disease and migraine comprising  
20 administering to a mammal in need of such treatment a therapeutically effective amount of a compound of (2*S*,3*R*,4*S*)-2-(2,2-Dimethylpentyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid.


25           77.    A method for treating coronary angina, cerebral vasospasm, acute and chronic renal failure, gastric ulceration, cyclosporin-induced nephrotoxicity, endotoxin-induced toxicity, asthma, LPL-related lipoprotein disorders, proliferative diseases, acute or chronic pulmonary hypertension, platelet aggregation, thrombosis, IL-2 mediated cardiotoxicity, nociception, colitis, vascular permeability disorders, ischemia-reperfusion injury, raynaud's disease and migraine comprising  
30 administering to a mammal in need of such treatment a therapeutically effective amount of a compound of (2*S*,3*R*,4*S*)-2-3-Fluoro-4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(2-(N-propyl-N-pentanesulfonyl)ethyl)-pyrrolidine-3-carboxylic acid.

78. A method for treating treating hypertension, congestive heart failure, restenosis following arterial injury, cerebral or myocardial ischemia or atherosclerosis comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1 in combination with one or more cardiovascular agents.


79. A method for treating treating hypertension, congestive heart failure, cerebral or myocardial ischemia or atherosclerosis comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 21 in combination with one or more cardiovascular agents.

80. A method for treating treating hypertension, congestive heart failure, cerebral or myocardial ischemia or atherosclerosis comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of (2*S*,3*R*,4*S*)-2-(2,2-Dimethylpentyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)-1-(*N*,*N*-di(*n*-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid in combination with one or more cardiovascular agents.

81. A process for the preparation of a compound of the formula:



wherein E is a carboxy-protecting group and R<sub>1</sub> and R<sub>2</sub> are independently selected from loweralkyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic and (heterocyclic)alkyl; or a salt thereof, comprising a) catalytic hydrogenation of a compound of the formula:




wherein E, R<sub>1</sub> and R<sub>2</sub> are defined as above and b) catalytic hydrogenation of the product of step a) in the presence of an acid or a mixture of acids.

82. The process of Claim 71 wherein E is loweralkyl, R<sub>1</sub> is aryl and R<sub>2</sub> is heterocyclic.

83. The process of Claim 71 wherein the hydrogenation catalyst is Raney nickel and the acid is a mixture of acetic acid and trifluoroacetic acid.


84. The process of Claim 71 wherein E is loweralkyl, R<sub>1</sub> is 4-methoxyphenyl and R<sub>2</sub> is 1,3-benzodioxol-5-yl.

85. A process for the preparation of a compound of the formula:



wherein E is a carboxy-protecting group and R<sub>1</sub> and R<sub>2</sub> are independently selected from loweralkyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic and (heterocyclic)alkyl; or a salt thereof, comprising

a) catalytic hydrogenation of a compound of the formula:



wherein E, R<sub>1</sub> and R<sub>2</sub> are defined as above,

b) catalytic hydrogenation of the product of step a) in the presence of an acid or a mixture of acids, and


c) epimerization of the product of step b) with a base.

86. The process of Claim 75 wherein E is loweralkyl, R<sub>1</sub> is aryl and R<sub>2</sub> is heterocyclic.

87. The process of Claim 75 wherein the hydrogenation catalyst is Raney nickel and the acid is a mixture of acetic acid and trifluoroacetic acid.

88. The process of Claim 75 wherein E is loweralkyl, R<sub>1</sub> is 4-methoxyphenyl and R<sub>2</sub> is 1,3-benzodioxol-5-yl.

89. A process for the preparation of a compound of the formula:




wherein E is a carboxy-protecting group, R<sub>1</sub> and R<sub>2</sub> are independently selected from loweralkyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic and (heterocyclic)alkyl and R<sub>3</sub> is R<sub>4</sub>-C(O)-R<sub>5</sub>-

wherein  $R_5$  is alkylene and  $R_4$  is  $(R_{11})(R_{12})N$ - wherein  $R_{11}$  and  $R_{12}$  are independently selected from

- (1) loweralkyl,
- (2) haloalkyl,
- (3) alkoxyalkyl,
- (4) haloalkoxyalkyl,
- (5) alkenyl,
- (6) alkynyl,
- (7) cycloalkyl,
- (8) cycloalkylalkyl,
- (9) aryl,
- (10) heterocyclic,
- (11) arylalkyl and
- (12) (heterocyclic)alkyl;
- (13) hydroxyalkyl,
- (14) alkoxy,
- (15) aminoalkyl, and
- (16) trialkylaminoalkyl,

or a salt thereof, comprising

a) catalytic hydrogenation of a compound of the formula:



wherein E,  $R_1$  and  $R_2$  are defined as above,

b) catalytic hydrogenation of the product of step a) in the presence of an acid or a mixture of acids,

c) epimerization of the product of step b) with a base and


d) alkylation of the product of step c) with a compound of the formula  $R_3-X$  wherein X is a leaving group and  $R_3$  is defined as above.

90. The process of Claim 79 wherein E is loweralkyl,  $R_1$  is aryl,  $R_2$  is heterocyclic and  $R_3$  is  $-CH_2C(O)NR_{11}R_{12}$  wherein  $R_{11}$  and  $R_{12}$  are independently selected from the group consisting of loweralkyl.


91. The process of Claim 79 wherein the hydrogenation catalyst is Raney nickel and the acid is a mixture of acetic acid and trifluoroacetic acid.

5 92. The process of Claim 79 wherein E is loweralkyl,  $R_1$  is 4-methoxyphenyl,  $R_2$  is 1,3-benzodioxol-5-yl,  $R_3$  is  $-\text{CH}_2\text{C}(\text{O})\text{N}(\text{n-Bu})_2$  and X is a halogen or sulfonate leaving group.

10 93. A process for the preparation of the substantially pure (+)-trans,trans optical isomer of the compound of the formula:




15 wherein E is loweralkyl,  $R_1$  is 4-methoxyphenyl and  $R_2$  is 1,3-benzodioxol-5-yl, or a salt thereof, comprising reacting a mixture of the (+) and (-) enantiomers of the compound of the formula:



20 wherein E is loweralkyl,  $R_1$  is 4-methoxyphenyl and  $R_2$  is 1,3-benzodioxol-5-yl with S-(+)- mandelic acid and separating the mandelate salt of the (+)-trans,trans optical isomer.

25 94. A compound of the formula:





wherein

Z is -C(R<sub>18</sub>)(R<sub>19</sub>)- or -C(O)- wherein R<sub>18</sub> and R<sub>19</sub> are independently selected from

5 hydrogen and loweralkyl;

n is 0 or 1;

R is -(CH<sub>2</sub>)<sub>m</sub>-W wherein m is an integer from 0 to 6 and W is

(a) -C(O)<sub>2</sub>-G wherein G is hydrogen or a carboxy protecting group,

(b) -PO<sub>3</sub>H<sub>2</sub>,

10 (c) -P(O)(OH)E wherein E is hydrogen, loweralkyl or arylalkyl,

(d) -CN,

(e) -C(O)NHR<sub>17</sub> wherein R<sub>17</sub> is loweralkyl,

(f) alkylaminocarbonyl,

(g) dialkylaminocarbonyl,

15 (h) tetrazolyl,

(i) hydroxy,




(j) alkoxy,






(k) sulfonamido,

(l) -C(O)NHS(O)<sub>2</sub>R<sub>16</sub> wherein R<sub>16</sub> is loweralkyl, haloalkyl, aryl or

20 dialkylamino,

(m) -S(O)<sub>2</sub>NHC(O)R<sub>16</sub> wherein R<sub>16</sub> is defined as above,





$R_1$  and  $R_2$  are independently selected from hydrogen, loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl and  $(R_{aa})(R_{bb})N-R_{cc}$ - wherein  $R_{aa}$  is aryl or arylalkyl,  $R_{bb}$  is hydrogen or alkanoyl and  $R_{cc}$  is alkylene, with the proviso that one or both of  $R_1$  and  $R_2$  is other than hydrogen;

$R_3$  is (a)  $R_4-C(O)-R_5-$ ,  $R_4-C(O)-R_5-N(R_6)-$ ,

wherein  $R_5$  is (i) a covalent bond, (ii) alkylene, (iii) alkenylene, (iv)  $-N(R_{20})-R_8-$  or  $-R_{8a}-N(R_{20})-R_8-$

wherein  $R_8$  and  $R_{8a}$  are independently selected from the group consisting of

alkylene and alkenylene and  $R_{20}$  is hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, cycloalkyl or cycloalkylalkyl or (v)  $-O-R_9-$  or  $-R_{9a}-O-R_9-$  wherein  $R_9$  and  $R_{9a}$  are independently selected from alkylene;
















$R_4$  and  $R_6$  are  $(R_{11})(R_{12})N-$  wherein  $R_{11}$  and  $R_{12}$  are independently selected from
















(1) hydrogen,


- (2) loweralkyl,
- (3) haloalkyl,
- (4) alkoxyalkyl,
- (5) haloalkoxyalkyl,
- (6) alkenyl,
- (7) alkynyl,
- (8) cycloalkyl,
- (9) cycloalkylalkyl,
- (10) aryl,
- (11) heterocyclic,
- (12) arylalkyl,
- (13) (heterocyclic)alkyl,
- (14) hydroxyalkyl,
- (15) alkoxy,
- (16) aminoalkyl,
- (17) trialkylaminoalkyl,
- (18) alkylaminoalkyl,
- (19) dialkylaminoalkyl,
- (25) carboxyalkyl,
- (26) (cycloalkyl)aminoalkyl,
- (27) (cycloalkyl)alkylaminoalkyl,
- (28) (heterocyclic)aminoalkyl, and
- (29) (heterocyclic)aminoalkyl, with the proviso that at least one of  $R_{11}$  and  $R_{12}$  is selected from heterocyclic, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, trialkylaminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, carboxyalkyl, (cycloalkyl)aminoalkyl, (cycloalkyl)alkylaminoalkyl, (heterocyclic)aminoalkyl, and (heterocyclic)alkylaminoalkyl;

or a pharmaceutically acceptable salt thereof.


95. A compound selected from the group consisting of:








wherein R is selected from the group consisting of:





96. A method for treating hypertension, congestive heart failure, restenosis following arterial injury, renal failure, cancer, colitis, reperfusion injury, angina, pulmonary hypertension, migraine, cerebral or myocardial ischemia, atherosclerosis, coronary angina, cerebral vasospasm, acute and chronic renal failure, gastric ulceration, cyclosporin-induced nephrotoxicity, endotoxin-induced toxicity, asthma, LPL-related lipoprotein disorders, proliferative diseases, acute or chronic pulmonary hypertension, platelet aggregation, thrombosis, IL-2 mediated cardiotoxicity, nociception, colitis, vascular permeability disorders, ischemia-reperfusion injury, Raynaud's disease, prostatic hyperplasia, and migraine comprising a therapeutically effective amount of a compound of claim 94, wherein said compound has an

attached charged functionality which reduces the degree of plasma protein binding of the compound.

5        97.     A method of improving the *in vivo* activity of compounds by reducing the amount of compound bound to protein by attaching a charged functionality to the compound.

10       98.     A method of claim 97 wherein the charged functionality carries a positive charge at physiological pH.

15       99.     A method for inhibiting bone metastases and metastatic growth in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.

20       100.    The method of Claim 99 wherein the bone metastases are osteoblastic.

25       101.    The method of Claim 100 wherein the osteoblastic bone metastases result from the spread of a primary cancer selected from breast, prostate, lung, kidney, thyroid, myeloma, lymphoma, sarcoma, osteosarcoma, and ovarian.

30       102.    The method of Claim 101 wherein the primary cancer is prostate cancer and the patient is male.

35       103.    The method of Claim 99 which additionally comprises co-administration of an anticancer drug.

40       104.    The method of Claim 103 wherein the anticancer drug agent is selected from leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

45       105.    The method of Claim 99 which additionally comprises the administration of radiation therapy.

50       106.    The method of Claim 99 which additionally comprises the administration of at least one therapeutic agent which impedes net bone loss.



107. The method of Claim 106 wherein the therapeutic agent is a bisphosphonate.

5 108. The method of Claim 99 wherein the endothelin antagonist is an ET<sub>A</sub>-selective endothelin antagonist.

10 109. A method for the inhibition of bone loss in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.

110. The method of Claim 109 wherein the patient has cancer.

15 111. The method of Claim 109 wherein the cancer is prostate cancer and the patient is male.

112. The method of Claim 109 which additionally comprises the administration of at least one therapeutic agent which impedes net bone loss.

20 113. The method of Claim 112 wherein the therapeutic agent is a bisphosphonate.

25 114. A method for the reduction of cancer-related pain in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.


115. The method of Claim 114 wherein the cancer is prostate cancer and the patient is male.

30 116. The method of Claim 114 which additionally comprises the administration of an anticancer drug.

35 117. The method of Claim 116 wherein the anticancer drug is selected from leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

118. The method of Claim 115 which additionally comprises the administration of radiation therapy.

119. A method for inhibiting bone metastases in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of a compound of formula I:



wherein

R is  $-(CH_2)_m-W$ ;


Z is selected from  $-C(R_{18})(R_{19})-$  and  $-C(O)-$ ;

$R_1$  and  $R_2$  are independently selected from hydrogen, loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl, and  $(R_{aa})(R_{bb})N-R_{cc}$ ,

with the proviso that one or both of  $R_1$  and  $R_2$  is other than hydrogen;

$R_3$  is selected from  $R_4-C(O)-R_5-$ ,  $R_4-R_{5a}-$ ,  $R_4-C(O)-R_5-N(R_6)-$ ,  $R_6-S(O)_2-R_7-$ ,  $R_{26}-S(O)-R_{27}-$ ,  $R_{22}-O-C(O)-R_{23}-$ , loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, aryloxyalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl, alkoxyalkoxyalkyl, and  $R_{13}-C(O)-CH(R_{14})-$ ;

$R_4$  and  $R_6$  are independently selected from  $(R_{11})(R_{12})N-$ , loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, haloalkenyl, haloalkoxyalkyl, haloalkoxy, alkoxyhaloalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, and



$R_5$  is selected from a covalent bond, alkylene, alkenylene,  $-N(R_{20})-R_8-$ ,  $-R_{8a}-N(R_{20})-R_8-$ ,  $-O-R_9-$ , and

-R<sub>9a</sub>-O-R<sub>9</sub>-;

R<sub>6</sub> is selected from loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl;

R<sub>7</sub> is a covalent bond, alkylene, alkenylene -N(R<sub>21</sub>)-R<sub>10</sub>-, and -R<sub>10a</sub>-N(R<sub>21</sub>)-

5 R<sub>10</sub>-;

R<sub>8</sub> is selected from alkylene and alkenylene;

R<sub>9</sub> is alkylene;

R<sub>10</sub> is selected from alkylene and alkenylene;

R<sub>11</sub> and R<sub>12</sub> are independently selected from hydrogen, loweralkyl, haloalkyl,

10 alkoxyalkyl, haloalkoxyalkylalkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclic, arylalkyl, (heterocyclic)alkyl, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, and carboxyalkyl;

R<sub>13</sub> is selected from amino, alkylamino and dialkylamino;

R<sub>14</sub> is selected from aryl and R<sub>15</sub>-C(O)-;

15 R<sub>15</sub> is selected from amino, alkylamino and dialkylamino;

R<sub>16</sub> is selected from loweralkyl, haloalkyl, aryl and dialkylamino;

R<sub>17</sub> is loweralkyl;

R<sub>18</sub> and R<sub>19</sub> are independently selected from hydrogen and loweralkyl;

R<sub>20</sub> is selected from hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl,

20 haloalkoxyalkyl, cycloalkyl and cycloalkylalkyl;

R<sub>21</sub> is selected from hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl and arylalkyl;

R<sub>22</sub> is selected from a carboxy protecting group and heterocyclic;

R<sub>23</sub> is selected from covalent bond, alkylene, alkenylene and -N(R<sub>24</sub>)-R<sub>25</sub>-;

25 R<sub>24</sub> is selected from hydrogen and loweralkyl;

R<sub>25</sub> is alkylene;

R<sub>26</sub> is selected from loweralkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl and alkoxy-substituted haloalkyl;

30 R<sub>27</sub> is selected from alkylene and alkenylene;

R<sub>5a</sub> is selected from alkylene and alkenylene;

R<sub>7a</sub> is alkylene;

R<sub>8a</sub> is selected from alkylene and alkenylene;

R<sub>9a</sub> is alkylene;

35 R<sub>10a</sub> is selected from alkylene and alkenylene;

R<sub>aa</sub> is selected from aryl and arylalkyl;

R<sub>bb</sub> is selected from hydrogen and alkanoyl;

$R_{CC}$  is alkylene;

m is 0-6;


n is 0 or 1;

z is 0-5;

5 E is selected from hydrogen, loweralkyl and arylalkyl;

G is selected from hydrogen and a carboxy protecting group; and

W is selected from  $-C(O)_2-G$ ;  $-PO_3H_2$ ,  $-P(O)(OH)(E)$ ,  
 $-CN$ ,  $-C(O)NHR_{17}$ , alkylaminocarbonyl, dialkylaminocarbonyl, tetrazolyl, hydroxy,  
 alkoxy, sulfonamido,  $-C(O)NHS(O)_2R_{16}$ ,  $-S(O)_2NHC(O)R_{16}$ ,



or a pharmaceutically acceptable salt thereof.

120. The method of Claim 119 wherein the bone metastases are osteoblastic.

121. The method of Claim 120 wherein the osteoblastic bone metastases result from the spread of a primary cancer selected from breast, prostate, lung, kidney, thyroid, myeloma, lymphoma, sarcoma, osteosarcoma, and ovarian.

122. The method of Claim 121 wherein the primary cancer is prostate cancer and the patient is male.

123. The method of Claim 119 which additionally comprises the administration of an anticancer drug.


124. The method of Claim 123 wherein the additional anticancer drug is selected from leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

125. The method of Claim 119 which additionally comprises the administration of radiation therapy.

126. The method of Claim 119 which additionally comprises the administration of at least one therapeutic agent which impedes net bone loss.

127. The method of Claim 126 wherein the therapeutic agent is a bisphosphonate.

128. A method for the inhibition of bone loss in cancer patients which comprises administering to the patient in need thereof a therapeutically effective amount of a compound of formula I:



wherein

R is  $-(\text{CH}_2)_m\text{-W}$ ;

Z is selected from  $-\text{C}(\text{R}_{18})(\text{R}_{19})-$  and  $-\text{C}(\text{O})-$ ;


R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen, loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl, and (R<sub>aa</sub>)(R<sub>bb</sub>)N-R<sub>cc</sub>-;

with the proviso that one or both of R<sub>1</sub> and R<sub>2</sub> is other than hydrogen;

R<sub>3</sub> is selected from R<sub>4</sub>-C(O)-R<sub>5</sub>-, R<sub>4</sub>-R<sub>5a</sub>-, R<sub>4</sub>-C(O)-R<sub>5</sub>-N(R<sub>6</sub>)-, R<sub>6</sub>-S(O)<sub>2</sub>-R<sub>7</sub>-, R<sub>26</sub>-S(O)-R<sub>27</sub>-, R<sub>22</sub>-O-C(O)-R<sub>23</sub>-, loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, aryloxyalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl, alkoxyalkoxyalkyl, and R<sub>13</sub>-C(O)-CH(R<sub>14</sub>)-

R<sub>4</sub> and R<sub>6</sub> are independently selected from (R<sub>11</sub>)(R<sub>12</sub>)N-, loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic)alkyl,

alkoxyalkyl, hydroxyalkyl, haloalkyl, haloalkenyl, haloalkoxyalkyl, haloalkoxy, alkoxyhaloalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, and



R<sub>5</sub> is selected from a covalent bond, alkylene, alkenylene, -N(R<sub>20</sub>)-R<sub>8</sub>-, -R<sub>8a</sub>-  
 5 N(R<sub>20</sub>)-R<sub>8</sub>-, -O-R<sub>9</sub>-, and  
 -R<sub>9a</sub>-O-R<sub>9</sub>-;

R<sub>6</sub> is selected from loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl;

R<sub>7</sub> is a covalent bond, alkylene, alkenylene -N(R<sub>21</sub>)-R<sub>10</sub>-, and -R<sub>10a</sub>-N(R<sub>21</sub>)-  
 10 R<sub>10</sub>-;

R<sub>8</sub> is selected from alkylene and alkenylene;

R<sub>9</sub> is alkylene;

R<sub>10</sub> is selected from alkylene and alkenylene;

R<sub>11</sub> and R<sub>12</sub> are independently selected from hydrogen, loweralkyl, haloalkyl,  
 15 alkoxyalkyl, haloalkoxyalkylalkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl,  
 heterocyclic, arylalkyl, (heterocyclic)alkyl, hydroxyalkyl, alkoxy,  
 aminoalkyl, trialkylaminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, and carboxyalkyl;

R<sub>13</sub> is selected from amino, alkylamino and dialkylamino;

R<sub>14</sub> is selected from aryl and R<sub>15</sub>-C(O)-;

20 R<sub>15</sub> is selected from amino, alkylamino and dialkylamino;

R<sub>16</sub> is selected from loweralkyl, haloalkyl, aryl and dialkylamino;

R<sub>17</sub> is loweralkyl;

R<sub>18</sub> and R<sub>19</sub> are independently selected from hydrogen and loweralkyl;

R<sub>20</sub> is selected from hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl,  
 25 haloalkoxyalkyl, cycloalkyl and cycloalkylalkyl;

R<sub>21</sub> is selected from hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl,  
 haloalkoxyalkyl, aryl and arylalkyl;

R<sub>22</sub> is selected from a carboxy protecting group and heterocyclic;

R<sub>23</sub> is selected from covalent bond, alkylene, alkenylene and -N(R<sub>24</sub>)-R<sub>25</sub>-;

30 R<sub>24</sub> is selected from hydrogen and loweralkyl;

R<sub>25</sub> is alkylene;

R<sub>26</sub> is selected from loweralkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl,  
 cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl and alkoxy-  
 substituted haloalkyl;

35 R<sub>27</sub> is selected from alkylene and alkenylene;

R<sub>5a</sub> is selected from alkylene and alkenylene;

R<sub>7a</sub> is alkylene;

R<sub>8a</sub> is selected from alkylene and alkenylene;

R<sub>9a</sub> is alkylene;

5 R<sub>10a</sub> is selected from alkylene and alkenylene;

R<sub>aa</sub> is selected from aryl and arylalkyl;

R<sub>bb</sub> is selected from hydrogen and alkanoyl;

R<sub>cc</sub> is alkylene;

m is 0-6;

10 n is 0 or 1;


z is 0-5;

E is selected from hydrogen, loweralkyl and arylalkyl;

G is selected from hydrogen and a carboxy protecting group; and

W is selected from -C(O)<sub>2</sub>-G; -PO<sub>3</sub>H<sub>2</sub>, -P(O)(OH)(E),

15 -CN, -C(O)NHR<sub>17</sub>, alkylaminocarbonyl, dialkylaminocarbonyl, tetrazolyl, hydroxy, alkoxy, sulfonamido, -C(O)NHS(O)<sub>2</sub>R<sub>16</sub>, -S(O)<sub>2</sub>NHC(O)R<sub>16</sub>,



or a pharmaceutically acceptable salt thereof.


20

129. The method of Claim 128 wherein the cancer is prostate cancer and the patient is male.

25 130. The method of Claim 128 which additionally comprises the administration of at least one therapeutic agent which impedes net bone loss.

131. The method of Claim 130 wherein the therapeutic agent is a bisphosphonate.

132. A method for the reduction of cancer-related pain which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula I:



wherein

R is  $-(CH_2)_m-W$ ;


Z is selected from  $-C(R_{18})(R_{19})-$  and  $-C(O)-$ ;

R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen, loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl, and  $(R_{aa})(R_{bb})N-R_{cc}-$ ,

with the proviso that one or both of R<sub>1</sub> and R<sub>2</sub> is other than hydrogen;

R<sub>3</sub> is selected from R<sub>4</sub>-C(O)-R<sub>5</sub>-, R<sub>4</sub>-R<sub>5a</sub>-, R<sub>4</sub>-C(O)-R<sub>5</sub>-N(R<sub>6</sub>)-, R<sub>6</sub>-S(O)<sub>2</sub>-R<sub>7</sub>-, R<sub>26</sub>-S(O)-R<sub>27</sub>-, R<sub>22</sub>-O-C(O)-R<sub>23</sub>-, loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, aryloxyalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl, alkoxyalkoxyalkyl, and R<sub>13</sub>-C(O)-CH(R<sub>14</sub>)-

R<sub>4</sub> and R<sub>6</sub> are independently selected from (R<sub>11</sub>)(R<sub>12</sub>)N-, loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, haloalkenyl, haloalkoxyalkyl, haloalkoxy, alkoxyhaloalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, and



R<sub>5</sub> is selected from a covalent bond, alkylene, alkenylene,  $-N(R_{20})-R_8-$ ,  $-R_{8a}-N(R_{20})-R_8-$ ,  $-O-R_9-$ , and  $-R_{9a}-O-R_9-$ ;

R<sub>6</sub> is selected from loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl;



R<sub>7</sub> is a covalent bond, alkylene, alkenylene -N(R<sub>21</sub>)-R<sub>10</sub>-, and -R<sub>10a</sub>-N(R<sub>21</sub>)-R<sub>10</sub>-;

R<sub>8</sub> is selected from alkylene and alkenylene;

R<sub>9</sub> is alkylene;

5 R<sub>10</sub> is selected from alkylene and alkenylene;

R<sub>11</sub> and R<sub>12</sub> are independently selected from hydrogen, loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkylalkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclic, arylalkyl, (heterocyclic)alkyl, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, and carboxyalkyl;

10 R<sub>13</sub> is selected from amino, alkylamino and dialkylamino;

R<sub>14</sub> is selected from aryl and R<sub>15</sub>-C(O)-;

R<sub>15</sub> is selected from amino, alkylamino and dialkylamino;

R<sub>16</sub> is selected from loweralkyl, haloalkyl, aryl and dialkylamino;

R<sub>17</sub> is loweralkyl;

15 R<sub>18</sub> and R<sub>19</sub> are independently selected from hydrogen and loweralkyl;

R<sub>20</sub> is selected from hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, cycloalkyl and cycloalkylalkyl;

R<sub>21</sub> is selected from hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl and arylalkyl;

20 R<sub>22</sub> is selected from a carboxy protecting group and heterocyclic;

R<sub>23</sub> is selected from covalent bond, alkylene, alkenylene and -N(R<sub>24</sub>)-R<sub>25</sub>-;

R<sub>24</sub> is selected from hydrogen and loweralkyl;

R<sub>25</sub> is alkylene;

R<sub>26</sub> is selected from loweralkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl and alkoxy-substituted haloalkyl;

R<sub>27</sub> is selected from alkylene and alkenylene;

R<sub>5a</sub> is selected from alkylene and alkenylene;

R<sub>7a</sub> is alkylene;

30 R<sub>8a</sub> is selected from alkylene and alkenylene;

R<sub>9a</sub> is alkylene;

R<sub>10a</sub> is selected from alkylene and alkenylene;

R<sub>aa</sub> is selected from aryl and arylalkyl;

R<sub>bb</sub> is selected from hydrogen and alkanoyl;

35 R<sub>cc</sub> is alkylene;

m is 0-6;

n is 0 or 1;


z is 0-5;

E is selected from hydrogen, loweralkyl and arylalkyl;

G is selected from hydrogen and a carboxy protecting group; and

W is selected from -C(O)<sub>2</sub>-G; -PO<sub>3</sub>H<sub>2</sub>; -P(O)(OH)(E),

- 5 -CN, -C(O)NHR<sub>17</sub>, alkylaminocarbonyl, dialkylaminocarbonyl, tetrazolyl, hydroxy, alkoxy, sulfonamido, -C(O)NHS(O)<sub>2</sub>R<sub>16</sub>, -S(O)<sub>2</sub>NHC(O)R<sub>16</sub>,



or a pharmaceutically acceptable salt thereof.

10 133. The method of Claim 132 wherein the cancer is prostate cancer and the patient is male.

15 134. The method of Claim 132 which additionally comprises the administration of an anticancer drug.

20 135. The method of Claim 134 wherein the additional anticancer drug is selected from leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

136. A method for inhibiting bone metastases in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of a compound of formula IIIa




IIIa.

1. The first step is to identify the problem or goal.

11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65  
 66  
 67  
 68  
 69  
 70  
 71  
 72  
 73  
 74  
 75  
 76  
 77  
 78  
 79  
 80  
 81  
 82  
 83  
 84  
 85  
 86  
 87  
 88  
 89  
 90  
 91  
 92  
 93  
 94  
 95  
 96  
 97  
 98  
 99  
 100  
 101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111  
 112  
 113  
 114  
 115  
 116  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523  
 524  
 525  
 526  
 527  
 528  
 529  
 530  
 531  
 532  
 533

145. The method of Claim 138 wherein the endothelin antagonist is an ET<sub>A</sub>-selective endothelin antagonist.

5 146. A method for the inhibition of bone loss in cancer patients which comprises administering to the patient in need thereof a therapeutically effective amount of a compound of formula IIIa




IIIa.

10 147. The method of Claim 146 wherein the cancer is prostate cancer and the patient is male.

15 148. The method of Claim 146 which additionally comprises the administration of at least one therapeutic agent which impedes net bone loss.

149. The method of Claim 148 wherein therapeutic agent is a bisphosphonate.

20 150. A method for the reduction of cancer-related pain which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula IIIa



IIIa.

151. The method of Claim 150 wherein the cancer is prostate cancer and the patient is male.

152. The method of Claim 150 which additionally comprises the administration of an anticancer drug.

153. The method of Claim 152 wherein the anticancer drug is selected from leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

154. A method for preventing new bone metastases in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.

155. A method for inhibiting metastatic growth in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.

156. A method for inhibiting bone turnover in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.

157. A compound according to Claim 1 of formula (I) wherein n is zero; Z is -CH<sub>2</sub>- wherein R<sub>18</sub> and R<sub>19</sub> are hydrogen; R is C(O)-G wherein G is hydrogen; R<sub>1</sub> is aryl substituted with one substituent selected from methoxy, methoxyethoxy, and isopropoxyethoxy; R<sub>2</sub> is 1,3-benzodiox-5-yl; R<sub>3</sub> is R<sub>4</sub>-C(O)-R<sub>5</sub>- wherein R<sub>5</sub> is methylene and R<sub>4</sub> is selected from (R<sub>11</sub>)(R<sub>12</sub>)N- and (R<sub>11a</sub>)(R<sub>12a</sub>)N-N(H)-; one of R<sub>11</sub> and R<sub>12</sub> is hydrogen and the other is selected from arylalkyl and diarylalkyl wherein each aryl group of the diarylalkyl is substituted with methyl or ethyl; and one of R<sub>11a</sub> or R<sub>12a</sub> is alkyl and the other is aryl.

158. A compound according to Claim 1 of formula (I) wherein n is zero; Z is -CH<sub>2</sub>- wherein R<sub>18</sub> and R<sub>19</sub> are hydrogen; R is C(O)-G wherein G is hydrogen; R<sub>1</sub> is phenyl substituted with one substituent selected from methoxy, methoxyethoxy, and isopropoxyethoxy; R<sub>2</sub> is 1,3-benzodiox-5-yl; R<sub>3</sub> is R<sub>4</sub>-C(O)-R<sub>5</sub>- wherein R<sub>5</sub> is methylene and R<sub>4</sub> is selected from (R<sub>11</sub>)(R<sub>12</sub>)N- and (R<sub>11a</sub>)(R<sub>12a</sub>)N-N(H)-; one of R<sub>11</sub> and R<sub>12</sub> is hydrogen and the other is selected from phenylalkyl and diphenylalkyl wherein each phenyl group of the diphenylalkyl is substituted with methyl or ethyl; and one of R<sub>11a</sub> or R<sub>12a</sub> is alkyl and the other is phenyl.

159. A compound according to Claim 1 of formula (II) wherein n is zero; Z is -CH<sub>2</sub>- wherein R<sub>18</sub> and R<sub>19</sub> are hydrogen; R is C(O)-G wherein G is hydrogen; R<sub>1</sub> is aryl substituted with one substituent selected from methoxy, methoxyethoxy, and isopropoxyethoxy; R<sub>2</sub> is 1,3-benzodiox-5-yl; R<sub>3</sub> is R<sub>4</sub>-C(O)-R<sub>5</sub>- wherein R<sub>5</sub> is methylene and R<sub>4</sub> is selected from (R<sub>11</sub>)(R<sub>12</sub>)N- and (R<sub>11a</sub>)(R<sub>12a</sub>)N-N(H)-; one of R<sub>11</sub> and R<sub>12</sub> is hydrogen and the other is selected from arylalkyl and diarylalkyl wherein each aryl group of the diarylalkyl is substituted with methyl or ethyl; and one of R<sub>11a</sub> or R<sub>12a</sub> is alkyl and the other is aryl.

160. A compound according to Claim 1 of formula (II) wherein n is zero; Z is -CH<sub>2</sub>- wherein R<sub>18</sub> and R<sub>19</sub> are hydrogen; R is C(O)-G wherein G is hydrogen; R<sub>1</sub> is phenyl substituted with one substituent selected from methoxy, methoxyethoxy, and isopropoxyethoxy; R<sub>2</sub> is 1,3-benzodiox-5-yl; R<sub>3</sub> is R<sub>4</sub>-C(O)-R<sub>5</sub>- wherein R<sub>5</sub> is methylene and R<sub>4</sub> is selected from (R<sub>11</sub>)(R<sub>12</sub>)N- and (R<sub>11a</sub>)(R<sub>12a</sub>)N-N(H)-; one of R<sub>11</sub> and R<sub>12</sub> is hydrogen and the other is selected from phenylalkyl and diphenylalkyl wherein each phenyl group of the diphenylalkyl is substituted with methyl or ethyl; and one of R<sub>11a</sub> or R<sub>12a</sub> is alkyl and the other is phenyl.